PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine)
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 202 4
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 1A PHASE 1, OPEN -LABEL, AGE -DESCENDING, DOSE -FINDING STUDY TO 
EVALUATE THE SAFETY, TOLERABILITY ,AND IMMUNOGENICITY OF 
RESPIRATORY SYNCYTIAL VIRUS P REFUSION F SUBUNIT VACCINE 
(RSVpreF) IN CHILDREN 2 TO 18 YEARS OF AGE
Study Intervention Number: PF-06928316
Study Intervention Name: Respiratory  Syncytial Virus (RSV) Vaccine
US IND Number: 017931
EU CT Number: 2022- 503134- 32-00
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number: EMEA -002795- PIP02-21
Protocol Number: C3671016
Phase: 1
Sponsor Legal Address: Pfizer I nc.
66 Hudson Boulevard East
New York, NY 10001
Brief Title: A Phase 1 Study  of the Safet y, Tolerability ,and I mmunogenicity of RSVpreF 
in Children 2 to 18 Years of Age 
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this 
infor mation in confidence and not copy or disclose it to others (except where required by applicable law ) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer must 
be promptly notified.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 2Document History
Document Version Date
Amendment 1 09Feb2024
Original protocol 31 Jan 2023
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs and any  protocol administrative change 
letter(s). 
Protocol Amendment Summary of Changes Table
Amendment 1 (09 Feb2024)
Overall Rationale for the Amendment: 
This amendment is made t o address aCBER recommendation to amend the protocol design 
to be consistent with an early -phase clinical study .
Description of Change Brief Rationale Section # and Nam e
Substantial Modification(s)
Added the clinicaltrials.gov 
reference and sponsor legal address 
to the title page.To reflect thetrial posting to 
clinicaltrials.gov.Title page
Removed Phase 2/3 content . To address CBER feedback . Throughout protocol
Nonsubstantial Modification(s)
Updated the text with respect to the 
FDA approval of RSVpreF 
(Abrysvo® ) for marketing in 
individuals 60 years of age and 
older and pregnant individuals at 
32-36 w eeks of gestational age in 
the US and to 
approvals of 
prophylactic monoclonal antibodies 
for RSV .To provide updated information on 
approvals for theRSV vaccine and 
monoclonal antibodies .Section 1.1
Section 2
Section 11
Updated s afety profile and risk 
assessment information.To reflect current safety data 
regarding RSVpreF.Section 2.1
Section 2.3.1
Deleted p otential risk from risk 
assessment.The global SARS -CoV -2 pandemic
has ended per WHO and risk is no 
longer applicable.Section 2.3.1
Updated theorder of the 
prevaccination RSV serostatus 
procedure .Updated per PACL . Section 1.3.1 .
Section 8.10.1 where applicable
Added AESI surveillance through
theend of study participation .Updated per PACL #3 . Section 1.1
Section 1.3
Section 8.4.1
Section 8.4.8
Section 8.10 where applicable
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 3Description of Change Brief Rationale Section # and Nam e
Updated thetext to provide mor e
clarity regarding the analysis of 
partially miss inge-diary data .To add clarification . Section 9.3.1
Section 9.4.1
Updated section to ensure 
compliance with current external 
regulations and internal policies .To ensure the protocol is compliant 
with current external regulations 
and internal policies .Section 10.1.3
Section 10.1.3.1
Section 10.1.3.2
Section 10.1.6
Section 10.1.7
Section 10.1.8
Section 10.1.9
Section 10.1.10
Made m inor editorial changes. To align with amendment and 
template updates and/or to improve 
clarity and navigation throughout 
the document for sites .All
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 4TABLE OF CONTENTS
LIST OF TABLES .....................................................................................................................9
1. PROTOCOL  SUMMARY ...................................................................................................10
1.1. Sy nopsis ..................................................................................................................10
1.2. Schema ....................................................................................................................18
1.3. Schedule of Activities .............................................................................................20
1.3.1.
.....................................................................................................................20
2. INTRODUCTION ...............................................................................................................24
2.1. Study  Rationale .......................................................................................................24
2.2. Background .............................................................................................................25
2.2.1. Clinical Overview .......................................................................................26
2.3.
Benefit/Risk Assessment.........................................................................................29
2.3.1. Risk Assessment
.........................................................................................30
2.3.2. Benefit Assessment .....................................................................................33
2.3.3. Overall Benefit/Risk Conclusion ................................................................33
3. OBJECTI VES, ENDPO INTS, AND ESTIMANDS ...........................................................33
4. STUDY DESIGN .................................................................................................................34
4.1. Overall Design .........................................................................................................34
4.1.1. Number of Participants
...............................................................................35
4.1.2. I ntervention Groups and Duration ..............................................................36
4.2. Scientific Rationale for Study  Design .....................................................................36
4.2.1. Diversity  of Study  Population ....................................................................36
4.3. Justification for Dose ..............................................................................................36
4.4. End of Study  Definition ..........................................................................................37
5. STUDY POPUL ATION
......................................................................................................37
5.1. I nclusion Criteria .....................................................................................................37
5.2. Exclusion Criteria ....................................................................................................38
5.3.Lifesty le Considerations ..........................................................................................39
5.4. Screen Failures ........................................................................................................40
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 55.5. Criteria for Temporarily  Delay ing 
Enrollment/Randomization/Administration of Study  Intervention ........................... 40
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................40
6.1. Study  Intervention(s) Administered ........................................................................41
6.1.1. Administration ............................................................................................41
6.1.2. Medical Devices .........................................................................................42
6.2. Preparation, Handling, Storage, and Accountability ...............................................42
6.2.1. Preparation and Dispensing ........................................................................43
6.3. Assignment to Study I ntervention ...........................................................................44
6.4. Blinding
...................................................................................................................44
6.4.1. Blinding of Participants ..............................................................................44
6.4.2. Blinding of Site Personnel ..........................................................................44
6.4.3. Blinding of the Sponsor
..............................................................................44
6.4.4. Breaking the Blind ......................................................................................44
6.5. Study  Intervention Compliance ...............................................................................44
6.6. Dose Modification ...................................................................................................44
6.7. C ontinued Access to Study  Intervention After the End of the Study ......................44
6.8. Treatment of Overdose
............................................................................................45
6.9. Prior and Concomitant Therap y
..............................................................................45
6.9.1. Prohibited Concomitant Vaccinations and Treatments ..............................45
6.9.2. Permitted Concomitant Vaccinations and Treatments
...............................46
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................46
7.1. Discontinuation of Study  Intervention ....................................................................46
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......47
7.2.1. Withdrawal of Consent ...............................................................................48
7.3. L ost to Follow -Up...................................................................................................48
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ............................... 49
8.1. Administrative Procedures ......................................................................................49
8.1.1. Telehealth Visits .........................................................................................50
8.2. Efficacy  and/or Immunogenic ity Assessments .......................................................50
8.2.1. Efficacy  Assessments ................................ ................................ ................. 50
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 68.2.2. I mmunogenicit y Assessments ....................................................................50
8.2.3. Biological Samples .....................................................................................51
8.3. Safet y Assessments .................................................................................................51
8.3.1. Phy sical Examinations ................................................................................52
8.3.2. Vital Signs ..................................................................................................52
8.3.3. Clinical Safety  Laboratory  Assessments ....................................................52
8.3.4. Reactogenicit y Electronic Diary .................................................................52
8.3.4.1. Grading Scales ...........................................................................53
8.3.4.2. L ocal Reactions .........................................................................53
8.3.4.3. Sy stemic Events ................................ ................................ ........ 54
8.3.4.4. Fever ..........................................................................................55
8.3.5. Stopping Rules
............................................................................................56
8.3.6. Randomization and Vaccination After a Stopping Rule Is Met .................57
8.4. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................57
8.4.1. Time Peri od and Frequency
 for Collecting AE and SAE Information .......58
8.4.1.1. Reporting SAEs to Pfizer Safety ...............................................59
8.4.1.2. Recording Nonserious AEs and SAEs on the CRF
...................59
8.4.2. Method of Detecting AEs and SAEs ..........................................................59
8.4.3. Follow -Up of AEs and SAEs ......................................................................59
8.4.4. Regulatory
 Reporting Requirements for SAEs ...........................................60
8.4.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................60
8.4.5.1. Exposure During Pregnancy ......................................................61
8.4.5.2. Exposure Du ring Breastfeeding ................................................62
8.4.5.3. Occupational Exposure .............................................................63
8.4.6. Cardiovascular and Death Events ...............................................................63
8.4.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................63
8.4.8. Adverse Events of Special Interest .............................................................63
8.4.8.1. Lack of Efficacy ........................................................................64
8.4.9. Medical Device Deficiencies ................................ ................................ ......64
8.4.9.1. Time Period for Detecting Medical Device Deficiencies ......... 64
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 78.4.9.2. Follow -Up of Medical Device Deficiencies..............................64
8.4.9.3. Prompt Reporting of Device Deficiencies to the Sponsor ........65
8.4.9.4. Regulatory  Reporting Requirements for Device 
Deficiencies .......................................................................................65
8.4.10.
Vaccination Errors....................................................................................65
8.5. Pharmacokinetics ....................................................................................................66
8.6. Genetics ...................................................................................................................66
8.6.1. Specified Genetics ......................................................................................66
8.7. Biomarkers ................................ ................................ ................................ .............. 66
8.8. I mmunogenicit y Assessments .................................................................................66
8.9. Health Economics ...................................................................................................67
8.10. Study  Procedures ...................................................................................................67
8.10.1. Visit 1 – Screening and Vaccination Visit (Clinic; Day 1) ......................67
8.10.2. Visit 2 
– 1-Week Follow -Up Visit (Telehealth; 6 to 8 Day s After 
Vaccination on Day  1) .....................................................................................69
8.10.3. Visit 3 
– 1-Month Follow -Up Visit (Clinic; 28 to 35 Day s After 
Visit 1) .............................................................................................................70
8.10.4. Visit 4 
– 6-Month Follow -Up Visit (Telehealth; 175 to 189 Day s 
After Visit 1) ....................................................................................................70
8.11. Unscheduled Visit for Fever or a Grade 3 or Suspected Grade 4 Reaction ..........71
8.12. Communication and Use of Technology ...............................................................72
9. STATI STICAL CONSI DERATIONS
................................................................................73
9.1. Statistical Hy pothesis ..............................................................................................73
9.2. Analy sis Sets ...........................................................................................................73
9.3. Statistical Analy ses.................................................................................................74
9.3.1. General Considerations ...............................................................................74
9.3.1.1. Analy ses for Binary  Data ..........................................................74
9.3.1.2. Analy ses for Continuous Data ...................................................74
9.3.2. Primary  Endpoint(s)/Estimand(s) Anal ysis................................................75
9.3.3. Secondary  Endpoint(s)/Estimand(s) Anal ysis............................................76
9.4. I nterim Anal yses.....................................................................................................76
9.4.1. Analy sis Timing ..........................................................................................76
9.5. Sample Size Determinati
on.....................................................................................76
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 810. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ................................ ................................ ................................ .......... 77
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............77
10.1.1. Regulatory and Ethical Considerations ....................................................77
10.1.1.1. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................77
10.1.2. Financial Disclosure .................................................................................78
10.1.3. I nformed Consent/Assent Process ............................................................78
10.1.3.1. Electronic Consent
..................................................................79
10.1.3.2. Remote Consent
......................................................................80
10.1.4. Data Protection .........................................................................................80
10.1.5. Committees Structure ...............................................................................81
10.1.5.1. Data Monitoring Committee ...................................................81
10.1.6. Dissemination of Clinical Study  Data ......................................................81
10.1.7. Data Qualit y Assurance ............................................................................82
10.1.8. Source Documents ....................................................................................84
10.1.9. Use of Medical Records ............................................................................84
10.1.10. Study  and Site Start and Closure ............................................................85
10.1.11. Publication Policy ...................................................................................86
10.1.12. Sponsor’s Medically  Qualified Individual ..............................................86
10.2. Appendix 2: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................88
10.2.1. Definition of AE .......................................................................................88
10.2.2. Definition of an SAE ................................................................................89
10.2.3. Recording/Reporting and Follow
-Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................90
10.2.4. Reporting of SAEs
....................................................................................94
10.3. Appendix 3: Contraceptive and Barrier Guidance ................................................94
10.4. Appendix 4: L iver Safety : Suggested Actions and Follow -Up Assessments .......95
10.5. Appendix 5: Kidney  Safety  Monitoring Guidelines .............................................97
10.5.1. Laboratory  Asses sment of Change in Kidney
 Function and 
Detection of Kidney  Injury ..............................................................................97
10.5.2. Age -Specific Kidney  Function Calculation Recommendations ...............97
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 910.5.2.1. Adolescents (12 Years to <18 Years) —Cockcroft -Gault 
Formula ..............................................................................................97
10.5.2.2. Children (2 Years to <12 Years) —Modified Schwartz 
Equation
.............................................................................................97
10.5.3. Adverse Event Grading for Kidney  Safet y Laboratory  
Abnormalities ...................................................................................................97
10.6. Appendix 6: AEs, ADEs, SAEs, SADEs, USADEs, and Device 
Deficiencies: Definitions and Procedures for Recording, Evaluating, 
Follow -
Up, and Reporting in Medical Device Studies .............................................98
10.6.1. Definition of AE and ADE .......................................................................98
10.6.2. Definition of SAE, SADE, and USADE ..................................................98
10.6.3. Definition of Device Deficiency ...............................................................99
10.6.4. Recording/Reporting and Follow
-Up of Medical Device 
Deficiencies ......................................................................................................99
10.6.5. Reporting of SAEs
..................................................................................101
10.6.6. Reporting of SADEs ...............................................................................101
10.7. Appendix 7: Abbreviations
.................................................................................102
11. REFERENCES ................................................................................................................106
LIST OF TABLES
Table 1. Participants ................................ ................................ ............................... 35
Table 2. Local Reaction Grading Scale ..................................................................54
Table 3. Systemic Event Grading Scale for Participants ≥2 Years of Age ............55
Table 4. Scale for Fever ..........................................................................................56
Table 5. Primary  Endpoint Anal yses......................................................................75
Table 6. Secondary  Endpoint Analy ses..................................................................76
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 101.PROTOCOL SUMMARY
1.1.Synopsis
Protocol Title:
A Phase 1, Open-L abel, Age -Descending, Dose-F inding Study  to Evaluate the Safet y, 
Tolerability , and Immunogenicity  of Respiratory  Syncytial Virus Prefusion F Subunit 
Vaccine (RSVpreF) inChildren 2 to18 Y ears of Age 
Brief Title:
A Phase 1 Study  of the 
Safet y, Tolerability, and Immunogenicit y of RSVpreF in Children 
2to 18 Years of Age 
Regulatory Agency Identification Number(s):
US IND Number: 017931
EU CT Num ber: 2022- 503134 -32-00
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number: EMEA -002795- PIP02 -21
Protocol Num ber: C3671016
Phase: 1
Rationale :
RSV is the leading cause of LRTIamong infants and y oung children globally .
Pfizer is developing a vaccine to protect against RSV disease. The vaccine, RSVpreF, 
contains 2 stabilized prefusion RSV Fglycoproteins in equal amounts in a lyophilized dosage 
form for reconstitution. On 31 May  2023 and 21 Aug 2023, the FDA approved RSVpreF 
(Abry svo®)for marketing in individuals 60 years of age and older and in pregnant 
individuals, respectivel y. On 23 Aug 2023, the European Commission granted marketing 
authorization for RSVpreF to help protect infants through maternal immunization a ndto 
protect older adults. Additional applications are under review by  other regulatory  agencies 
around the world.
Thisproposed pediatric Phase 1 study  (C3671016) will evaluate different dose levels 
ofRSVpreF in children 2 to 18 yearsof age to identify  the dose level for Phase 2/3 trials in 
this age cohort . In this stud y, children will be considered high risk if they  are 
5 to 18 years 
of age and have certain chronic medical conditions, or if they  are 2 to 5years of age and are 
healthy  or have certain medical conditions. Children 2 to  5 years of age are considered at 
high risk of increased morbidity  due to RSV infection based on their age alone .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 11Objectives , Endpoints ,and Estimands :
Objectives Endpoints Estimands
Prim ary: Prim ary: Prim ary:
To describe the safety and tolerability 
of RSVpreF at each dose level in 
children 5 to 18 years of age and 
children 2 to 5 years of age.Prom pted local reactions 
(pain at the injection site, 
redness, and swelling).
Prom pted systemic events 
(fever, vomiti ng, diarrhea, 
headache, fatigue/tiredness , 
muscle pain, and joint 
pain).
AEs.
SAEs .
NDCMCs .In participants receiving 1 dose of 
study intervention at each dose level, 
for each age stratum:
The percentage of participants 
reporting local reactions within 
7days after vaccination .
The percentage of participants 
reporting systemic events within 
7 days after vaccination .
The percentage of participants 
reporting AEs from vaccination 
through 1 month after 
vaccination .
The percentage of participants 
reporting SAEs throughout the 
study .
The percentage of participants 
reporting NDCMCs throughout 
the study .
Secondary: Secondary: Secondary:
To describe the immune responses 
elicited by RSVpreF at each dose 
level in children 5 to 18 years of age 
and children 2 to 5 years of age.RSV A and RSV B NTs. In participants in compliance with 
the key protocol criteria (evaluable 
immunogenicity population):
GMT sof NT for RSV A and 
RSV B 1 m onth after 
vaccination.
GMT sof NT for RSV A and 
RSV B before vaccination.
GMFR sof NT for RSV A and 
RSV B from before vaccination 
to 1 month after vaccination.
To describe the cell -mediated 
immune response in children 
5 to  18years of age and children 
2 to  5years of age.RSV F antigen –specific 
CD4+ T cells secreting 
IFN .
RSV F antigen –specific 
CD4+ T cells secreting 
IL-4.In participants in compliance with 
the key protocol criteria (evaluable 
immunogenicity population):
Median frequenc iesof RSV
Fantigen –specific CD4+ T cells
expressing IFNbefore 
vaccination and 1 month after 
vaccination .
Median frequenc iesofRSV
Fantigen –specific CD4+ T cells 
expressing IL-4before 
vaccination and 1 month after 
vaccination .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 12Overall Design:
This is a Phase 1, open -label, age -descending, dose -finding study  ofthesafety , tolerability , 
and immunogenicit y of RSVpreF in RSV -seropositive children 2 to  18 years of age . 
Participants will be divided into 2age strata: 5 to 18 years and 2 to 5 years. All 
participants will receive 1dose of RSVpreF.
A single dose of RSV preF 120 µg will be administered to the older age stratum first .Upon 
confirmation of an acceptable safet y profile b y the I RC, dose administration will proceed in 
the 2- to 5-yearagestratum with 60 µ g. Pending IRC approval, the younger age stratum 
will receive a single 120-µ g dose of thevaccine . The older age stratum may also receive a 
single dose of RSVpreF 60 µg . Stopping rules will apply .
Dependent upon safet y and/or immunogenicit y data generated during the course of this 
study , it is possible that dose levels may  not be started, may  be terminated early , and/or may  
be added atlevels below the lowest stated dose.
All p articipant sinthe 2
-to 5-yearagestratum will require a blood sample to assess RSV
serostatus during the screening visit ,and only those who are seropositive willbe
administered RSVpreF on Day 1.All participants 5years of age and older will be considered 
RSV seropositive and will not require a screening test.
Participants will have a baseline blood draw prior to vaccination on Day 1 and a postdose 
blood draw 1 month after vaccination to assess immunogenicit y.
Additional blood will be required for PBMC isolation and will b e collected simultaneously  
with the immunogenicity sample ,both on D ay 1 and again 1 month after vaccination. 
Frequencies of RSV Fantigen –specific CD4+ Tcells secreting specific cy tokines will be 
measure dboth before and after vaccination.
The study  duration for each participant will be approximately  6months.
Internal Review Committee
This study  will use an IRC. The I RC is independent of the study
 team and includes only  
internal members. The IRC charter describe s in detail the roles of the IRC members.
Number of Participants:
This is an open
-label dose -finding study . Asingle dose of RSVpreF 120µgwill be given to 
approximately  40 participants in the 5 -to 18-yearagestratum first, equally  divided between 
healthy  children and those with 
high-risk chronic medical conditions. U pon I RC approval , a 
dose of 60 µg will be given to 20 participants in the 2- to 5-year age stratum .If,per the 
IRC,
60 µg isdetermined to be safe and tolerable ,another 20 participants in the 2- to 5-year
agestratum will receive the 120
-µgdose. TheIRC may  also request thata single dose of 
RSVpreF 60 µgbe given to approximately  40 participants in the 5 -to 18-year age stratum. 
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 13Dependent upon safet y and/or immunogenicit y data generated during the course of this 
study , it is possible that dose levels may  not be started, may  be terminated early , and/or may  
be added atlevels below the lowest stated dose. Approximate ly60 to 120 participants are 
expected to be enrolled .
Age Stratum (Years) Number of 
Participants
2 to 5 ~20/~20a
5 to 18 ~40/~40a,b
Total ~60-120
a.Up to 2 dose levels of RSVpreF (120 µg and 60 µg) will be tested in participants.
b.Approximately 40 participants 5 to 18 years old w ill be enrolled, with ~20 healthy participants and 
~20 participants with high -risk chronic medical conditions receiving each dose level.
Study Population :
Inclusion and exclusion criteria are listed below:
Inclusion Criteria
Participants must meet the following inclusion criteria to be eligible for enrol lment in the 
study :
Age and Sex:
1. P articipants 2 to 18 years of age at enrollment (signing of the ICD or providing 
assent to participate) at Visit 1.
Disease Characteristics:
2.
Participants 2 to 18 years of age should either be healthy  or be considered by  the 
investigator to be at high risk of RSV disease based on the presence of 1of the 
following chronic medical conditions:
Cystic fibrosis
Medically treated a sthma
Other chronic respiratory diseases and malformations of the lung
Down sy ndrome
Neuromuscular disease
Cerebral palsy
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 14Hemody namicall y significant or s ymptomatic congenital heart disease
Details of the chronic medical conditions listed above are further defined in the 
investigator s ite file.
Other Inclusion Criteria:
1.All participants 2 to 5 years of age must be seropositive for RSV as confirmed by  
serology .
2.Participants’ parent(s)/legal guardian(s) and participants, as age appropriate, who are 
willing and able to comply with all scheduled visits, investigational plan, laboratory  
tests, and other study  procedures ,. Participants’ parent(s)/legal guardian(s) should be 
available for telephone contact with site staff for the duration of the stud y.
3.
The participant’s parent(s)/legal guardian is capable of giving signed informed 
consent as described in Appendix 1 , which includes compliance with the 
requirements and restrictions listed in the I CD and in this protocol. Depending on the 
age of the participant and according to lo cal requirements, participants will also be 
asked to provide assent as appropriate (verbal or written).
Exclusion Criteria
Participants with any  of the following characteristics/conditions will be excluded:
Medical Conditions:
1.Immunocompromised individuals associated with known or suspected 
immunodeficiency , as determined by  history  and/or laboratory /physical examination.
2.Individuals with a history of autoimmune disease or an active autoimmune disease 
requiring therapeutic intervention, including but not li mited to sy stemic lupus 
erythematosus. Note: Stable t ype 1 diabetes and hypoth yroidism are permitted.
3.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk 
of study  participation or, in the investigator’s judgment, make the participant 
inappropriate for the study .
4.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of t he study  intervention(s).
5. Bleeding diathesis or condition associated with prolonged bleeding that would, in the 
opinion of the investigator, contraindicate intramuscular injection.
6.Individuals with a history  of epileps y orother seizure disorders, or a his tory of 
seizures and/or other neurological complications following vaccination .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 15Prior/Concomitant Therapy:
7.Previous vaccination with any  licensed or investigational RSV vaccine or planned 
receipt during stud y participation. Children who may have been exposed to 
investigational RSV vaccines through maternal immunization will be permitted.
8.Receipt of investigational or approved monoclonal antibodies against RSV within 
6months before stud y intervention administration , or planned receipt throughout the 
study .
9.Receipt of blood/plasma products or immunoglobulins within 28 day sbefore study  
intervention administration , or planned receipt throughout the stud y.
10.Receipt of chronic s ystemic treatment with known immunosuppressant medications 
(including cytotoxic agents orsystemic corticosteroids), orradiotherap y,within
60days before study intervention administration, or planned receipt throughout the 
study .
Note: Systemic corticosteroids are defined as those administered for ≥ 14 day s at a 
dose of ≥20 mg/day  of prednisone or equivalent (eg, for cancer or an autoimmune 
disease). Inhaled/nebulized, intra -articular, intrabursal, or topical (skin, eyes, or ears) 
corticosteroids are permitted.
Prior/Concurrent Clinical Study Experience:
11.Participation in o ther studies involving study  intervention within 28 day s prior to 
study  entry  and/or for the duration of study  participation.
Diagnostic Assessments:
Not applicable .
Other Exclusion Criteria:
12.Investigator site staff directly  involved in the conduct of the study  and their family  
members , site staff otherwise supervised by  the investigator, and sponsor and sponsor 
delegate employ ees directly  involved in the conduct of the study and their family  
members .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 16Study Arms and Duration :
Study Arms and Study Interventi ons
Intervention Name PF-06928316 (RSVpreF)
Arm  Nam e
(group of participants receiving a specific vaccine 
or no vaccine)Active vaccine group
Unit Dose Strength(s) 120 µgand/or 60 µg
Type Vaccine
Route of Adm inistration Intramuscular
Use Experimental
IMP or NIMP/AxMP IMP
Dose finding will begin at 120 µgof RSV preF in participants 5 to 18 years of age. The IRC 
will review safety  data (e -diary  and AE
s) acquired up to 7 day s after vaccination once a 
minimum of 10 and up to approximately 40 participants have been vaccinated .Upon IRC 
confirmation of an acceptable safet
y profile in the 5 -to18-year-olds, dos e administration
may commence at 60 µgof RSV preF in participants 2 to 5 years of age. The same process 
will be followed before vaccina ting with 120 µ
gof RSV preF in the 2-to 5-year-olds . Upon 
IRC review , RSVpreF 60 µg may be given to pa rticipants in the 5- to 18-year agestratum .
Study Duration :
The study  duration for each participant will be approximately  6months.
Statistical Methods :
This Phase 1 study  is descriptive; thus, sample size is not based on an y statistical criteria. 
Safety  and immunogenicity  data will be descriptively  summarized for this cohort ,and 
immunogenicit y data in this cohort may be descriptively  compared with other study  results.
Ethical Considerations :
The available safet y, immunogenicit y, and effectiveness data from ongoing clinical trials for 
RSVpreF support a favorable benefit/risk p rofile. Anticipated AEs after vaccination are 
expected to be similar to those observed following vaccination with the same vaccines (mild 
to moderate reactogenicity), which are manageable using routine symptom -driven standard 
of care.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 17Because of the histor y of vaccine -mediated ERD following immunization of RSV -naïve 
infants in the 1960s with an FI-RSV vaccine ,this study will be limited to seropositive 
children only  and will assess the cellular response (Th1/Th2 balance) to RSVpreF .Th1- and 
Th2- specific cy tokines will be used as a surrogate to characterize the cellular immune 
response and predisposition to enhanced disease. Unlike the FI-RSV vaccine, RSVpreF is an 
F gly coprotein subunit stabilized in the prefusion conformation, elicits strong neutralizing 
antibodies as established in the adult studies, and has already  shown efficacy  in preventing 
LRTI in older adults and severe LRTI in infants born to vaccinated mothers. Available 
evidence indicates that RSVpreF is efficacious and is unlikely  toconfer any  risk of enhanced 
disease.
The expected safet y profile of this vaccine therefore supports initiation of this clinical study .
Based on the experience with RSV preF, the potential risks are:
Local reactions and s ystemic events such as injection site redness, injection site 
swelling, and injection site pain; and fever, fatigue /tiredness
, headache, muscle pain, 
and joint pain.
Guillain -Barrésyndrome. I n Study  C3671013, conducted in adults 60 y ears of age 
and older, there were 2 cases of Guillain -Barrésyndrome or its variants identified 
with a plausible temporal relationship with vaccination among >18,000 individuals 
who received RSVpreF. Both cases had confounding factors or alternative etiology .
Other events of special interest include atrial fibrill ation, poly neuropathy , preterm 
birth (delivery  at <37 0/7 weeks’ gestation), and hy pertensive disorders of pregnancy .
Theoretical risk for RSV vaccine –elicited ERD .
The study  procedure -related risks include:
Venipuncture will be performed during the stud y.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 181.2.Schema
5-to <18 -Year A ge Stratum 2-to <5 -Year A ge Stratum
Phase 1
All participants receive RSVp reFPhase 1
All participants receive RSVp reF
120 µg(n=40) IRCa60 µg(n=20)
          IRCbIRCb
60 µg(n=40) 120 µg(n=20)
          IRCc          IRCc
RSVpreF dose level selected RSVpreF dose level selected
a.Progression of the study to the younger age stratum will occur upon confirmation of an acceptable safety 
assessment of data accumulated up to 7 days after vaccination at the 120 -µglevel, once a minimum of 10 
and up to approximately 40 participants have been vaccinated in participants from the 5 -to 18-year age 
stratum.
b
.In eachage strat um, based on safety assessment of data accumulated up to 7 days after vaccination, the 
IRC may request a different dose level of RSVpreF to be tested.
c.The IRC will chooseadose level for each age stratum depending on safety ,tolerability , and 
immunogenicity data accumulated from 7 days after dose administration in each age stratum.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine)
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 202 4
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 19
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 201.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the Study  Assessments And Procedures section of 
the protocol for detailed information on each procedure and assessment required for compliance with the protocol.
The investigator may  sche dule visits (unplanned visits) in additio n to those listed in the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
1.3.1.
Visit Number
Abbreviations used in this 
table may be found in 
Appendix 7.1 2 3 4 Notes
Visit Description Screening and 
Vaccination1-Week 
Follow -UpVisit1-Month 
Follow -UpVisit6-Month 
Follow -UpVisit
Visit Window ( Days) Day 1 6 to 8 Days After 
Vaccination Day 128 to 35 Days After Visit 
1175 to 189 Days After
Visit 1Day relative to start of 
study intervention
administration (Day 1).
Type of Visit Clinic Telehealth Clinic Telehealth
Obtain informed consent 
and assent (if applicable)X Informed consent should 
be obtained prior to 
undergoing any 
study -specific procedures.
See Section 10.1.3 for 
additional information.
Assign participant 
numberX
Obtain demography and 
significant medical 
history dataX
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 21Visit Number
Abbreviations used in this 
table may be found in 
Appendix 7.1 2 3 4 Notes
Visit Description Screening and 
Vaccination1-Week 
Follow -UpVisit1-Month 
Follow -UpVisit6-Month 
Follow -UpVisit
Visit Window ( Days) Day 1 6 to 8 Days After 
Vaccination Day 128 to 35 Days After Visit 
1175 to 189 Days After
Visit 1Day relative to start of 
study intervention
administration (Day 1).
Type of Visit Clinic Telehealth Clinic Telehealth
Perform p hysical 
examination (including 
height and w eight)X Physical examinations to 
be completed before 
administration of study 
intervention.
Measure prevaccination 
temperatureX If the temperature is 
38°C (100.4 °F), 
vaccination delay criteria 
apply. See Section 5.5.
Collect nonstudy vaccine 
informationX X X X
Collect prohibited 
medication useX X X X
Confirm eligibility X
Revie w temporary  delay 
criteriaX
Collect blood sample for 
immunogenicity~5 mLfor children 
10years of age and 
~10mL for children 10to 
18 years of age~5 mL for children 
10years of age and 
~10mL for children 10 to 
18years of ageAny AEs occurring up to 
48 hours after the blood 
draw  must be recorded 
(see Section 8.4.1 ).
Collect blood sample for
PBMC isolationUp to 1 mL per year of 
age,but no more than 
10mLUp to 1 mL per year of 
age,but no more than 
10mLAny AEs occurring up to 
48 hours after the blood 
draw  must be recorded 
(see Section 8.4.1 ).
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 22Visit Number
Abbreviations used in this 
table may be found in 
Appendix 7.1 2 3 4 Notes
Visit Description Screening and 
Vaccination1-Week 
Follow -UpVisit1-Month 
Follow -UpVisit6-Month 
Follow -UpVisit
Visit Window ( Days) Day 1 6 to 8 Days After 
Vaccination Day 128 to 35 Days After Visit 
1175 to 189 Days After
Visit 1Day relative to start of 
study intervention
administration (Day 1).
Type of Visit Clinic Telehealth Clinic Telehealth
Perform RSV serostatus test 
(for children 2 to <5 years of 
age only).X RSV serostatus must be 
tested and seropositiv ity 
confirmed prior to 
vaccination (for 
participants 2 to <5 years 
of age). 
Obtain randomization
number and study 
intervention allocationX
Study intervention 
administrationX See Section 6.1for 
additional information.
Assess acute reactions for 
at least 30 minutes after 
study intervention 
administrationX See Section 6.1.1 for 
additional information.
Provide instructions on 
the reactogenicity e -diary 
completion requirements 
to the participant’s 
parent(s)/leg al guardian 
and assist with 
downloading the app or 
issue a provisioned 
device, if requiredX Parent(s)/legal guardian 
will record reactogenicity 
events each evening for 
7days, starting on the day 
of vaccination.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 23Visit Number
Abbreviations used in this 
table may be found in 
Appendix 7.1 2 3 4 Notes
Visit Description Screening and 
Vaccination1-Week 
Follow -UpVisit1-Month 
Follow -UpVisit6-Month 
Follow -UpVisit
Visit Window ( Days) Day 1 6 to 8 Days After 
Vaccination Day 128 to 35 Days After Visit 
1175 to 189 Days After
Visit 1Day relative to start of 
study intervention
administration (Day 1).
Type of Visit Clinic Telehealth Clinic Telehealth
Provide thermometer and 
measuring deviceX See Section 8.3for 
additional information.
Revie w reactogenicity 
e-diary data (daily review 
is optim al during the 
active diary period)Days 1 through 7
Contact the participant if 
they report a severe 
reaction or fever in their 
e-diary; arrange an 
unscheduled visit if 
requiredDays 1 through 7
Review ongoing 
reactogenicity e -diary 
symptoms reported as 
present on the last day of the 
e-diary reporting period and 
obtain stop datesX X X Ongoing reactogenicity 
e-diary events must be 
followed up to obtain stop 
dates as described in 
Section 8.3.4 .
Collect AEs as appropriate X X X See Section 8.4for 
additional information.
Collect SAEs , AESIs ,and 
NDCMCs as appropriateX X X X See Section 8.4for 
additional information.
Collect reactogenicity 
e-diary device, if applicableX
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 242.INTRODUCTION
RSVpreF is being investigated for the prevention of RSV disease in 2 -to5-year-old 
children and 
in 5-to18 - year-oldchildren with high -risk chronic medical conditions.
2.1.Study Rationale
RSV is the primary  viral cause of LRT Iamong infants and y oung children globall y.1
A recent review of the global RSV burden estimated that, worldwide, RSV causes 3. 6million 
hospitalizations each y ear among children under 5 y ears of age, most of which occur in 
infants.2However, emerging evidence suggests that RSV disease not only  occurs at a high
ratein infancy ,
but also cause smedicall yattended illness throughout the first 5 y ears of 
life.3,4,5,6,7,8Theburden of RSV among health y children 5 years of age and older is less 
frequentl y studied ;
however, it is well established that certain underl ying medical conditions,
including cystic fibrosis, medically treated asthma, other chronic respiratory  diseases a nd 
malformations of the lung, Down syndrome, neuromuscular disorders, cerebral pals y, and 
hemody namicall y significant or s ymptomatic congenital heart disease ,predispose children to
increased risk of morbidity  due to RSV.6,9,10,11,12In this study , children will be considered
“high risk” ofincreased morbidity  due to RSV if they  are 5 to  18 yearsof age and have 1of 
the aforementioned chronic medical conditions, or if they  are 2 to 5 yearsof age andhave 
1 of the aforementioned chronic medical conditions or are health y. The younger age group is
considered at risk based on age alone.
Currently , there is no vaccine proph ylaxisapproved 
for use in children 2 to <18 y ears of age
to protect against RSV disease. Aprophy lactic humaniz ed monoclonal antibody , palivizumab 
(Synagis, AstraZeneca), that binds the RSV F gl ycoprotein, is recommended for use onl y in 
high-risk infants, and can prevent infant RSV disease.13,14A newer humanized monoclonal 
antibody  targeting the prefusion c onformation of RSV F gl ycoprotein, nirsevimab 
(Beyfortus, AstraZeneca and Sanofi) ,was recent ly approved to prevent RSV LRTD in 
neonates and infants born during or entering their first RSV season and for children up to 
24months of age who remain vulnerabl e to severe RSV disease through their second RSV 
season .15
However, antibodies that are currentl y licensed or in development for children 2 years of 
age may  be impractical for older children because of the challenges around administration of 
an appropriate volume and the limited half -
life compared to the period of risk in children up 
to 5 y ears of age. With the lack of antiviral therapies for treatment of RSV disease, the 
limited usefulness of monoclonal antibody  prophy laxis, and the absence of a licensed v accine 
to prevent RSV disease, there exists an unmet medical need for agents that can provide 
prophy laxis against RSV disease in children 2to 5 years of age and children 5 to  18 years 
of age who are at high risk of RSV disease.
Study  C3671016 is a Phase 1 study  of the safety , tolerability ,and immunogenicity  of 
RSVpreF in 
children 2 to18 years of age ,including children 5 to 18 years of age with 
high-risk medical conditions .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 252.2.Background
In a recent review of the global RSV burden, the annual rate of RSV -associated 
hospitalization for children 1 to  5 years of age in high -income countries was 1. 6per 1000.2
Studies conducted in Europe corroborate this global review and have shown that 
RSV -associated hospitalization still occurs after infancy, with rates between 6.4 and 15.0 per 
1000 annually  among 1 -year-olds and between 0.6 and 2.3 per 1000 annually  among children 
2 to 4 y ears of age.3,4Studies in the US and UK have shown similar ranges of RSV disease 
burden estimates for these age groups.3,4,5
In addition to the hospitalized burden of RSV among children 1 to 5 years of age, research 
suggests that RSV may  also cause a significant outpatient burden in this age group. 
Apopulation -based study  conducted by  the US CDC showed that when looking at all 
medically attended cases of RSV (ie, hospitalized and outpatient), 78% occurred in children 
1 to 5years of age. This finding highlighted that a lar ger burden of RSV- associated disease 
exists in this age group than previousl y thought.7Therefore, it is commonly considered that 
children in this age group are at higher risk for RSV disease. Furthermore, household studies 
assessing RSV transmission patterns suggest that children 1 to 5 years of age may  be the 
primary  reservoirs for RSV transmission within families. These data suggest that prevention 
of RSV in thi s age group may help indirectl y protect young children who are at highest risk 
of hospitalization and severe disease.16,17,18Despite these studies, there remains a knowledge 
gap on the full disease burden and potential vaccine benefit for this age group .7
On 31 May  2023 and 21 Aug 2023, the FDA approved RSVpreF for marketing in individuals 
60 years of age and older and in pregnant individuals, respectivel y.19,20On 23 Aug 2023, the 
European Commission granted marketing authorization for RSVpreF to help protect infants 
through maternal immunization and to protect older adults.21Additional applications are 
under review b y other regulatory agencies around the world.
Because of the history  of vaccine -
mediated RSV disease enhancement following 
immunization of RSV -naïve infants in the 1960s with a nFI-RSV ,22this study will be limited 
toseropositive children only  and will assess T- cell response sto RSVpreF , specificall ythe 
Th1/Th2 profile .Unlike the FI -RSV vaccine , RSVpreF is an F gl ycoprotein subunit
stabilized in the prefusion conformation and thus elicits a high ratio of neutraliz ing to 
nonneutrali zing antibodies more closel y matching the profile in naturall y exposed individuals 
where no disease enhancement has been observed. Furthermore, the vaccine has alread y 
shown efficacy  in preventing L RTI and severe L RTI in older adults and severe LRTI in 
infants born to vaccina ted mothers (refer to Section 2.2.1). Available evidence indicates that 
RSVpreF is efficacious and is unlikely  toconfer any  risk of enhanced disease.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 262.2.1. Clinical Overview
Adult Program Studies
The older adult program includes 2 Phase 1/2 studies, 3 Phase 3 studies, and a Phase 2a 
human challenge stud y.
In Phase 1/2 study  C3671001, 1233 healthy  adults 18 through 49 and 50 through 
85years of age received the 3 dose levels of RSVpreF (60 µ g, 120 µg, and 240 µ g), 
with or without Al(OH) 3, or placebo, administered with or without concomitant 
influenza vaccine . The results have shown that the vaccine was well tolerated and 
immunogenic in both age groups. RSVpreF elicited robust neutralizing responses 
against RSV A and RSV B 1 month after vaccination for both age groups across all 
vaccine dose levels and formula tions; these responses remained high through the 
12months after vaccination. In 616 vaccinated participants in the 50 -through 85 -year 
age group, RSV 50% NT GMFRs were high across all arms of the study , ranging 
from 9 to 13 from before vaccination to 1 mo nth after vaccination and from 3 to 
4from before vaccination to 12 months after vaccination for RSV A and RSV B. 
RSVpreF was safe and well tolerated when administered alone or with SIIV, with no 
major differences observed across all dose levels and formul ations. Most reported 
local reactions or s ystemic events were mild or moderate in severit y. The proportions 
of participants reporting AEs were generally similar across RSVpreF groups, and no 
SAEs were considered related to the investigational vaccine.
Phas e 1/2 study  C3671002, in 250 older adults 65 through 85 y ears of age, studied 
the3 dose levels of RSVpreF with Al(OH) 3or CpG/Al(OH) 3(60 µg, 120 µg, and 
240 µ g), given as a single dose or on a schedule of 2 doses administered 2 months 
apart. All RSVpreF doses and formulations elicited high RSV A –and 
RSV B–neutralizing antibody  GMTs 1 month after vaccination (GMFRs ranging 
from 4.8 to 11.6 and 4.5 to 14.1, respectivel y). CpG
-containing formulations did not 
further increase neutralizing GMTs compared to R SVpreF with or without Al(OH) 3. 
GMTs in all groups declined, but remained higher than baseline (before vaccination) 
and placebo (SIIV onl y) 12 months after vaccination (GMFRs ranging from 2.1 to 
3.5and 2.2 to 4.3, respectively ). No increase in GMTs was observed 1 month after 
Vaccination 2 (GMFR of 0.9). All doses and formulations were safe and well 
tolerated.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 27C3671014 is a completed Phase 3, multicenter, parallel -group, placebo- controlled, 
randomized, double -blind lot -consistency study in a population of up to 1000 healthy  
adults 18 to ≤ 49 years of age. The stud y examined the immune response and the 
safet y and tolerability profiles across 3 manufactured lots of RSVpreF when 
administered as a single 120 -µgdose to healthy  adults . The primary  anal yses showed 
that the ratios of neutralizing GMTs for the 3 manufactured RSVpreF lots 1 month 
after vaccination were equivalent, and that the 120-µ g dose of RSVpreF waswell 
tolerated and has an acceptable safet y profile.
A Phase 2a, Randomised, Double- Blind, Placebo -Controlled Study  to Evaluate the 
Safety , Immunogenicit y and Efficacy  of a Respiratory  Syncytial Virus Vaccine 
(RSVpreF) in a Virus Challenge Model in Healthy Adults ([STUDY_ID_REMOVED]) was 
conducted b y hV IVO in 70 healthy  participants 18 to 50 y ears of a ge. Participants
received a single dose of either 120 µg RSVpreF or placebo and 4 weeks later 
underwent intranasal challenge with RSV -A Memphis 37b virus. The 
immunogenicit y and efficacy of RSVpreF vaccination on virus replication, clinical 
symptoms, and i ncidence of sy mptomatic RSV infection 
following the intranasal 
challenge were evaluated. The primary  anal ysis of the human challenge study  showed 
that a 120-µ g dose of RSVpreF was well tolerated and has an acceptable safety  
profile. 
The stud y demonstrated 100% efficacy  of RSVpreF against 
RT-PCR–confirmed sy mptomatic infection.
C3671013 is an ongoing Phase 3, multicenter, randomized, double -blind, 
placebo- controlled 
study to assess the safet y, immunogenicity , and efficacy of 
Pfizer’s RSVpreF in prevention of RSV -associated L RTI in adults 60 y ears of age 
and older. Both health y adults and adults with stable chronic cardiopulmonary 
conditions are included. Approximately  10% of participants with stable chronic 
cardiopulmonary  conditions such as COPD, asthma, o r CHF have been enrolled. 
The study  enrolled over 3 7,000 participants, randomized to receive RSVpreF or 
placebo in a 1:1 ratio. This is an event -driven study  with a target of 59 first episodes 
of evaluable RSV -associated L RTI cases. I nterim anal ysisresul ts in Aug ust2022 
showed protection against L RTI-RSV defined by  
2or more s ymptoms, with VE of
66.7%. VE of 85.7% was observed in participants with a more severe disease primary  
endpoint of L RTI-RSV defined by  analy sis of 3 or more RSV -associated s ymptoms. 
The vaccine was well tolerated, with no safet y concerns .23On 31 May  2023, the FDA 
approved RSVpreF for individuals 60 y ears of age and older in the US.19On23 
August 2023, R SVpreF wasalso granted marketing authorization within the EU f or 
active immunization of adults 60 y ears of age and older for the prevention of LRTD
caused b y RSV .21
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 28C3671006 is a Phase 3, multicenter, parallel -group, placebo- controlled, randomized, 
double -blind study nearing completion. 1407 healthy  adults ≥ 65 years of age were
randomized 1:1 to 
either a coadministration group or a sequential -administration 
group. The intention was to demonstrate that the immune responses generated when a 
120-µg RSVpreF dose was coadministered with SIIV were noninferior to the immune 
responses when these products were adm inistered 4 weeks apart. The safet y and 
tolerability  of RSVpreF were also examined. The study  has yet to be anal yzed .
Maternal Program Studies
The maternal program includes Phase 2b and Phase 3 studies in pregnant women and a 
Phase 2b study  in nonpregnant 
women.
C3671003 is a completed Phase 2b multicenter, randomized, placebo -controlled study  
in up to 650 healthy  pregnant women 18 through 49 years of age who received 
RSVpreF at 120 µ g and 240 µg, formulated with or without Al(OH) 3, or placebo. 
The final analysis provided evidence of the good tolerability  and safet y of RSVpreF 
in maternal vaccine recipients and the safet y of maternal vaccination with RSVpreF 
for the infant.
C3671004 is a completed Phase 2b study  of 713 healthy  nonpregnant women 
18through 49 years of age. A total of 709 participants received 120 µg RSVpreF or 
240 µ g RSVpreF with Al(OH) 3or placebo, administered with or without concomitant 
Tdap. The stud y demonstrated a good safet y and tolerability profile, high immune 
responses, and noninfe riority  of the responses to RSVpreF when coadministered with 
Tdap, with RSV A and RSV B 50% NT GMRs of 0.97 and 0.96 at 1 month after 
vaccination.
C3671008 is a completed Phase 3, multicenter, randomized, double-blinded, 
placebo- controlled study  designed t o evaluate the efficacy  and safet y of maternal 
immunization with RSVpreF against MA -LRTI in infants. Healthy participants 
≤49 y ears of age between 24 and 36 weeks’ gestation received either RSVpreF 
120µg or the placebo. The study  enrolled approximately 7400 pregnant individuals. 
Primary  anal ysis results (data cutoff: September 2022) demonstrated a VE of 81.8% 
against severe MA -LRTI due to RSV in infants from birth through the first 90 days of 
life, with a high efficacy  of 69.4% demonstrated through the first 6 months of 
life. RSVpreF was well tolerated with no safet y concerns for both vaccinated 
individuals and their newborns.24Based on these data, approval of RSVpreF for the 
protection of infants through maternal immunization was received in the US an d EU ,
with additional applications under review b y regulatory agencies around the 
world .20
,21
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 292.3.Benefit/Risk Assessment
RSV is the primary  viral cause of LRT Iamong infants an d young children globall y.1
There is no 
approved direct vaccination to help protect against RSV disease in children. 
There is a proph ylactic humani zed monoclonal antibody , palivizumab (Sy nagis, 
AstraZeneca), that binds the RSV F gl ycoprotein, is recommended for use only  in high -risk 
infants, and can prevent infant RSV disease.13,14A newer humanized monoclonal antibody 
targeting the prefusion conformation of RSV F gly coprotein, nirsevimab (Bey fortus, 
AstraZeneca and Sa nofi) ,was recentl y approved to prevent RSV LRTD in neonates and 
infants born during or entering their first RSV season and for children up to 24 months of age 
who remain vulnerable to severe RSV disease through their second RSV season . However, 
antibodies that are currently  licensed or in development for children 2 years of age may  be 
impractical for older children because of the challenges around administration of an 
appropriate volume and the limited half -life compared to the period of risk in children up to 
5years of age. With the lack of antiviral therapies for treatment of RSV disease, the limited 
usefulness of monoclonal antibody  proph ylaxis, and the absence of a licensed vaccine to 
prevent RSV disease, there exists an unmet medical need for agents that can provide 
prophy laxis against RSV disease to children 2 to 5 years of age, and children 5 to  18 years 
of age who are at high risk of RSV
-associated LRTI .
More detailed information about the known and expected benefits and risks and reasonabl y 
expe cted AEs of RSVpreF may be found in the IB, which is the SRSD for this study .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 302.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) :RSVpreF
Pfizer has identified the most common 
risks for RSVpreF as local reactions, 
such as injection site redness, injection 
site swelling, and injection site pain ;
and systemic events ,such as fatigue, 
headache, diarrhea, joint pain, nausea, 
vomiting, muscle pain ,and feve r.
Guillain -Barré syndrome has been 
identified as a potential risk for 
RSVpreF.
Other events of interest include atrial 
fibrillation, polyneuropathy, preterm 
birth, and hypertensive disorders of 
pregnancy.
The identified adverse reactions in local 
product labels may vary depending on 
the requirements of the respective 
regulatory authorities (eg, EU -SmPC 
and USPI).These are common adverse reactions seen with 
other vaccines as well as RSVpreF.
Data available from completed and ongoing 
studies showed a low  incidence of severe or 
serious events, and no clinically concerning 
safety observations. The vaccine appears to be 
safe and w ell tolerated across the safety 
population and within demographic subgroups 
based on age, sex, and race/ethnicity.
In Study C3671013 , conducted in adults 
60years of age and older, there w as 1case of 
Guillain -Barré syndrome and 1case of Miller 
Fisher syndrome with a plausible temporal 
relationship with vaccination. Both cases had 
confounding factors or alternative etiolog ies. 
In Stu dy C3671013, conducted in adults 
60years of age and older, there w as a 
nonsignificant numerical imbalance in the 
number of cases of atrial fibrillation reported for 
individuals who received RSVpreF compared to 
individuals who received theplacebo. Most of
the participants who had atrial fibrillation and 
received RSVpreF had a pre -existing medical 
history of atrial fibrillation and/or cardiac 
disease.
In Study C3671008, conducted in pregnant 
individuals, there were no statistically 
meaningful imbalances bet ween RSVpreF and 
placebo recipients in the overall rates of preterm 
birth (5.7% [95% CI: 4.9, 6.5] versus 4.7% 
[95% CI: 4.1, 5.5], respectively). The study employs the use of a reactogenicity e-diary, which 
allows the investigator to monitor local reactions and systemic 
events in real time through an electronic portal.  Severe 
reactions will require an unscheduled telephone call, and visit 
if required, to be conducted per protocol.
Collection of AEs and SAEs throughout the study. 
IRC to review all safety data.
All participants will be observed for at least 30 minutes after 
vaccination.
Specific references to risks and events of interest are made 
within the ICD, with reporting instructions if a case is 
suspected.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 31Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) :RSVpreF
How ever, a numerical imbalance was observed 
in upper -middle -income countries betw een 
RSVpreF and placebo recipients. Outcomes in 
the premature infants were similar between the 2
groups.
In Study C3671008, conducted in pregnant 
individuals there was a non -significant 
numerical imbalance in hypertensive disorders 
of pregnancy reported for participants who 
received RSVpreF compared to participants who 
received theplacebo.  
The majority of preterm and hypertensive 
disorders occurred more than 30 days following 
vaccination.
Theoretical risk for RSV enhancement. RSVpreF is being evaluated in ongoing clinical 
studies. Pfizer’s immunization approach 
circumvents the risk of vaccine -mediated disease 
enhancement that was observed in the 1960s 
following direct immunization of RSV -naive 
infants with an FI -RSV. FI -RSV elicited a 
predominantly nonneutralizing antibody 
response and a Th2 -biased cell -mediated 
response, both of which are considered potential 
contributing factors to disease enhancement. 
During preclini cal studies, in a standard cotton 
rat infectious RSV challenge model, the FI -RSV 
showed pathological signs of causing disease 
enhancement, and the current Pfizer vaccine 
candidate, RSVpreF, did not. Unlike the 
FI-RSV, RSVpreF is an F glycoprotein subunit 
stabilized in the prefusion conformation. 
RSVpreF elicits strong neutralizing antibodies 
(and a high neutralizing to nonneutralizing ratio) 
as established in the adult studies and has Assessments of AEs and SAEs will be collected and reviewed 
throughout the study.
The study will be limited to seropositive children only and will 
assess the cellular response (Th1/Th2 balance) to RSVpreF. 
Th1-and Th2 -specific cytokines will be used as a surrogate to 
characterize the cellular immune response and predisposition to 
enhanced disease.
Assessment of individual cases for disease enhancement is 
challenging based on current understanding of the mechani sm 
of pathogenesis, thus evaluations of any adverse or unexpected 
imbalances in severe RSV cases may provide insight into a 
potential signal for this theoretical risk.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 32Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) :RSVpreF
already shown efficacy in preventing LRTI in 
older adults and severe LRTI in infants born to 
vaccinated mothers (refer to Section 2.2.1 ). 
Available evidence indicates that RSVpreF is 
efficacious and is un likely to confer any risk of 
enhanced disease.
Study Procedures
Venipuncture will be performed during 
the study.There is the risk of bleeding, bruising, 
hematoma formation, and infection at the 
venipuncture site.Only appropriately qualified personnel will obtain the blood 
draw .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 332.3.2. Benefit Assessment
Benefits to individual participants enrolled may  be:
Receipt of a potentiall y efficacious RSV vaccine.
Contributing to research to help others.
2.3.3. Overall Benefit /Risk Conclusion
Taking into account the measures to minimize risk to study  participants, the potential risks 
identified in association with RSVpreF are justifi ed by  the anticipated benefits that may  be 
afforded to participants.
3.OBJECTIVES, ENDPOINT S, AND ESTIMANDS
Objectives Endpoints Estimands
Prim ary: Prim ary: Prim ary:
To describe the safety and 
tolerability of RSVpreF at each 
dose level in children 5 to 18 years 
of age andchildren 2 to  5 years of 
age.Prom pted local reactions (pain 
at the injection site, redness, 
and swelling) .
Prom pted systemic events 
(fever, vomiting, diarrhea, 
headache, fatigue/tiredness, 
muscle pain, and joint pain) .
AEs.
SAEs .
NDCM Cs.In participants receiving 1 dose of 
study intervention at each dose 
level , for each age stratum:
The percentage of participants 
reporting local reactions 
within 7 days after 
vaccination.
The percentage of participants 
reporting systemic events 
within 7 days after 
vaccination.
The percentage of participants 
reporting AEs from 
vaccination through 1 month 
after vaccination .
The percentage of participants 
reporting SAEs throughout the 
study .
The percentage of participants 
reporting NDCMCs 
throughout the stu dy.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 34Objectives Endpoints Estimands
Secondary: Secondary: Secondary:
To describe the immune response 
elicited by RSVpreF at each dose 
level in children 5 to 18 years of 
age and children 2 to  5 years of 
age.RSV A and RSV B NTs. In participants in compliance with 
the key protocol criteria (evaluable 
immunogenicity population):
GMT sof NT for RSV A and 
RSV B 1 m onth after 
vaccination.
GMT sof NT for RSV A and 
RSV B before vaccination.
GMFR sof NT for RSV A and 
RSV B from before 
vaccination to 1 month after 
vaccination.
To describe the cell -mediated 
immune response in children 
5 to <18 years of age and children 
2 to <5 years of age .RSV F antigen –specific 
CD4+ T cells secreting IFN .
RSV F antigen –specific 
CD4+ T cells secreting IL -4.In participants in compliance with 
the key protocol criteria (evaluable 
immunogenicity population):
Median frequenc iesof RSV
Fantigen –specific 
CD4+ T cells expressing IFN 
before vaccination and 
1month after vaccination .
Median frequenc iesof RSV
Fantigen –specific 
CD4+ T cells expressing IL -4 
before vaccination and 
1month after vaccination .
4.STUDY DESIGN
4.1.Overall Design
This is a P hase 1 ,open -label, age -descending, dose -finding study  of the safety , tolerability , 
and immunogenicit yof RSVpreF in RSV -seropositive children 2 to <18yearsof age .
Participants will be divided into 2age strata: 5 to <18 years and 2 to < 5 years. All 
participants will receive 1dose of RSVpr eF.
A single dose of RSVpreF 120 µgwill be administered to the older age stratum first .Upon 
confirmation of an acceptable safet y assessment by  the IRC, dose administration willproceed 
in the 2- to < 5- yearagestratum with 60 µ g.Pending IRC approval, the younger age stratum 
willreceive 120 µg of vaccine. The IRC may  also request that a dose of RSVpreF 60 µgbe 
given in the older age stratum.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 35Dependent upon safet y and/or immunogenicit y data generated during the course of this 
study , it is possible that dose levels may  not be started, may  be terminated early , and/or may  
be added with dose le vels below the lowest stated dose.
Stopping rules will apply as detailed in Section 8.3.5 .
All p articipants within the 2-to <5 -yearagestratum will require a blood sample to be taken 
atthescreening visit to assess serostatus, and only those who are seropositive can beenrolled 
and administered RSVpreF onDay 1.All participants 5years of age and older will be 
considered RSV seropositive and will not require a screening test.
All participants will have blood drawn prior to vaccination on Day 1 and 1 month after 
vaccinat ion to assess immune response elicited after vaccination with RSVpreF. An 
additional whole blood sample will be obtained prior to vaccination on Day 1 and 1 month 
after vaccination for PBMC isolation. An analy sis of prespecified cy tokine s will be 
conducted to describe postvaccination cell -mediated immune response s 1month after 
vaccination.
4.1.1. Number of Participants
This is an open -label dose -finding study . Asingle dose of RSVpreF 120 µgwill be given to 
approximately 40 participants in the 5- to < 18-year age stratum first,equa lly divided between 
healthy  children and those with high -risk chronic medical conditions. Upon I RC approval, a 
dose of 60 µg will be given to 20 participants in the 2 -to <5-year age stratum. I f ,per the 
IRC, 60 µg is safe and tolerable , another 20 participants in the 2 -to < 5-year agestratum will 
receive the 120 -
µgdose. The I RC may  also request thata single dose of RSVpreF 60 µg be 
given to approximately  40 participants in the 5 -to < 18-year agestratum. Dependent upon 
safet y and/or immunogenicity data generated during the course of this study, it is possible 
that dose levels may  not be started, may be terminated early , and/or may  be added with dose 
levels below the lowest stated dose. Approximat ely 60 to 120 participants are expected to be 
enrolled in the Phase 1 cohort. See Table 1.
Table 1. P articipants
Age Stratum (Years) Number of 
Participants
2 to 5 ~20/~20a
5 to 18 ~40/~40a,b
Total ~60-120
a.Up to 2 dose levels of RSVpreF (120 µg and 60 µg) will be tested in participants.
b.Approximately 40 participants 5 to 18 years old w ill be enrolled in this study , with ~20 healthy 
participants and ~20 participants with high -risk chronic medical conditions receiving each dose level.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 364.1.2. Intervention Groups and Duration
Dose finding will begin with 120 µg of RSVpreF in participants 5 to 18 years of age. The 
IRC will review safet y data (e -diary  and AE s) acquired up to 7 day safter dos
e administration
once a minimum of 10 and up to approximately  40 participants have been vaccinated . Upon 
confirmation of an acceptable safet y assessment by  the IRC, dose administration may 
commence with 60 µg in participants 2 to 5 years of age. The same process with an IRC 
review of safet y data (e -diary  and AE s) acquired up to 7 day safter dos e administration at the 
low-dose level from participants 2 to 5 years of age 
will be followed before administering 
the120- µgdose to this younger stratum .
Inthe 
2-to 5-year age stratum , if 60 µg is considered unacceptable based on the safet y 
assessment, administration of the 120
-µgdose level will not commence. In this case, an 
optional lower dose level may  commence. Upon IRC review, RSVpreF 60 µgmay also be 
given to participants in the 5 -to 18-year age stratum .
Duration: The study  duration for each participant will be approximately  6month s.
4.2.Scientific Rationale for Study Design
See Section 2.1.
4.2.1. Diversity of Study Population
Reasonable attempts will be made to enroll participants with the distribution of 
characteristics to ensure that the study  population is representative of the population that will 
use RSVpreF in clinical practice.
4.3.Justification for Dose
The dose and formulation plan for this study is to start with 120 µg RSVpreF without any  
adjuvants in participants 5 to 18 years of age, before initiating the 60 -
µgdose level .
The FIH study  in adults 18 through 85 y ears of age evaluated the safety , tolerability , and 
immunogenicit y of 3 escalating RSVpreF dose levels of 60 µg, 120 µg, and 240 µ g, with or 
without Al(OH) 3, when administered alone or concomitantly  with SIIV (Study  C3671001).
A study  in older adults 65 through 85 years of age evaluated the safet y, tolerability , and 
immunogenicit y of 60 -
µg, 120 -µg, and 240 -µg RSVpreF doses formulated with 
Al(OH) 3or aCpG/Al(OH) 3adjuvant, or 240 µg RSVpreF with RSV antigens alone, wh en 
administered concomitantly  with SIIV (Study  C3671002).
A Phase 3 study  in adults 65 y ears of age and older evaluated the safety , tolerability , and 
immunogenicit y of 120 µg RSVpreF when administered concomitantly  with 
SIIV(Study C3671006).
A study  in he althy  adults 18 through 50 y ears of age evaluated the safety , immunogenicit y, 
and efficacy  of 120 µg RSVpreF in a virus challenge model ([STUDY_ID_REMOVED]).
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 374.4.End of Study Definition
The end of the stud y is defined as the date of the last visit of the last partici pant in the study .
A participant is considered to have completed the study  if he/she has completed all periods of 
the study , including the last visit.
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled , including 
participants across diverse and representative racial and ethnic backgrounds. If a 
prescreening tool is utilized for stud y recruitment purposes, it will include collection of 
information that reflects the enrollment of a diverse participant pop ulation including, where 
permitted under local regulations, age, sex, race, and ethnicity . The following eligibility  
criteria are designed to select participant s for whom participation in the study  is considered 
appropriate. All relevant medical and nonmed ical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol .
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1. P articipants 2 to 18 years of age at enrollment (signing of the ICD or providing 
assent to participate) at Visit 1.
Disease Characteristics:
2.Participants 2 to 18 years of age should either be healthy  or be considered by  the 
investigator to be at high risk of RSV disease based on the presence of 1of the 
following 
chronic medical conditions9,10,25:
Cystic fibrosis
Medically treated a sthma
Other chronic respiratory diseases and malformations of the lung
Down sy ndrome
Neuromuscular disease
Cerebral palsy
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 38Hemody namicall y significant or s ymptomatic congenital heart disease
Details of the chronic medical conditions listed above are further defined in the 
investigator s ite file.
Other Inclusion Criteria:
3. All participants 2 to 5 years of age must be seropositive for RSV as confirmed by  
serology .
4.Participants’ parent(s)/legal guardian(s) and participants, as age appropriate, who are 
willing and able to comply with all scheduled visits, investigational plan, laboratory  
tests, and other study procedures. Participants’ parent(s)/legal guardian(s) should be 
available for telephone contact with site staff for the duration of the stud y.
5.The participant’s parent(s)/legal guardian is capable of giving signed informed 
consent as described in Section 10.1, which includes compliance with the 
requirements and restrictions listed in the I CD and in this protocol. Depending on the 
age of the participant and according to local requirements, participants will also be 
asked to provide assent as appropriate (verbal or written).
5.2.
Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Immunocompromised individuals associated with known or suspected 
immunodeficiency , as determined by  history  and/or laboratory /physical examination.
2.Individuals with a history of autoimmune disease or an active autoimmune disease 
requiring therapeutic intervention, including but not limited to sy stemic lupus 
erythematosus. Note: Stable t ype 1 diabetes and hypoth yroidism are permitted.
3.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk 
of study  participation or, in the investigator’s judgment, make the par ticipant 
inappropriate for the study .
4.History  of severe adverse reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of the study  intervention(s).
5.Bleeding diathesis or condition associated with prolonged bl eeding that would, in the 
opinion of the investigator, contraindicate intramuscular injection.
6.Individuals with a history of epileps y or other seizure disorders, or a history of 
seizures and/or other neurological complications following vaccination.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 39Prior/ Concomitant Therapy:
7.Previous vaccination with any  licensed or investigational RSV vaccine or planned 
receipt during stud y participation. Children who may have been exposed to 
investigational RSV vaccines through maternal immunization will be permitted.
8.Receipt of investigational or approved monoclonal antibodies against RSV within 
6months before stud y intervention administration, or planned receipt throughout the 
study .
9.Receipt of blood/plasma products or immunoglobulins within 28 day s before study  
intervention administration, or planned receipt throughout the stud y.
10.Receipt of chronic s ystemic treatment with known immunosuppressant medications 
(including cy totoxic agents or sy stemic corticosteroids), or radiotherapy , within 
60days before study  interventi on administration, or planned receipt throughout the 
study .
Note: Systemic corticosteroids are defined as those administered for ≥ 14 day s at a 
dose of ≥20mg/day ofprednisone orequivalent (eg,forcancer oranautoimmune
disease). Inhaled/nebulized, intra -articular, intrabursal, or topical (skin, eyes, or ears) 
corticosteroids are permitted.
Prior/Concurrent Clinical Study Experience:
11.Participation in other studies involving study  intervention within 28 day s prior to 
study  entry  and/or for the duration of study  participation.
Diagnostic Assessments:
Not applicable .
Other Exclusion Criteria:
12.Investigator site staff directly  involved in the conduct of the study  and their family  
members , site staff otherwise supervised by  the investigator, and sponsor and sponsor 
delegate employ ees directly  involved in the conduct of the study and their family  
members.
5.3.Lifestyle Considerations
There areno lifesty le restrictions required for the participants in this study .
All pregnancies discovered in female participant sduring the stud y participation, which 
begins after obtaining informed consent as described in Section 8.4.1, will be recorded inthe 
CRF in addition to completing the EDP (Section 8.4.5.1 ) and EDB ( Section 8.4.5.2 )reporting 
process es.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 405.4.Screen Failure s
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. Minimal 
information includes demograph y, screen failure details, and an y SAE s.
Individuals who do not meet the criteria for participation in thi s study  (screen failure) may be 
rescreened under a different participant number.
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Administration of 
Study Intervention
The following conditions may  allow a participant to be vaccinated once the conditions have 
resolved and the participant is otherwise eligible:
Current febrile illness (temperature ≥38.0°C [ ≥ 100.4 °F]) or other acute illness within 
48hours before study
 intervention administration.
Receipt of an y live vaccine within 28days before study  intervention administration. 
Receipt of anynonlive vaccine (including COVID -19 vaccines authorized for 
temporary  or emergency use) within 14 day s before study  intervention administration.
Anticipated receipt of any nonstud y vaccine within 14 days af ter study  intervention 
administration at Visit 1 (before Day  15).
Receipt of short -term ( 14 day s) systemic corticosteroids (equivalent of ≥ 20 mg/day
of prednisone). Stud y intervention administration should be delayed until systemic 
corticosteroid use has been discontinued for at least 28 day s. Inhaled/nebulized, 
intra-articular, intrabursal, or topical ( skin, ey es, or ears ) corticosteroids are 
permitted.
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study  interventions are all prespecified investigational andmedical devices and other 
interventions (eg, surgical and behavioral) intended to be administered to the study 
participants during the study conduct.
For the purposes of this protocol, study  intervention refers to RSVpreF.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 416.1.Study Intervention(s) Admini stered
Study Intervention(s)
Intervention Name PF-06928316 (RSVpreF)
Arm  Nam e
(group of participants receiving 
a specific vaccine or no vaccine)Active vaccine group
Unit Dose Strength(s) 120 µgand/or 60 µg
Type Vaccine
Dose Form ulation The active ingredients in RSVpreF are 2 stabilized RSV prefusion 
Fantigens, in equal amounts from virus subgroups A and B, in a 
lyophilized dosage form for reconstitution. The RSVpreF formulation 
will contain 120 µg of the RSV prefusion F antigen. RSVpreF is 
supplied as a lyophilized white cake in a 2 -mL glass vial, with a 13 -mm 
lyophilization stopper, aluminum overseal, and flip -off cap.
RSVpreF will be reconstituted by a diluent consisting of sterile w ater in 
a PFS. The lyophilized RSVpreF formulation co ntains excipients that, 
after reconstitution, will yield a solution as detailed in the IB. The fill 
volume of the RSVpreF vial and diluent PFS are designed such that the 
120-µg vaccine dose is delivered by injecting the entire contents of the 
syringe.
The 60-µg vaccine dose is delivered by injecting 0 .25 mL of a 
graduated syringe content.
Route of Adm inistration Intramuscular
Use Experimental
IMP or NIMP/AxMP IMP
Sourcing Provided centrally by the sponsor
Packaging and Labeling The vaccine will be packaged within cartons labeled by Pfizer or its 
designee in accordance with current guidelines and applicable local and 
legal regulatory requirements.
Study Arms(s)
Arm  Title Active vaccine
Arm  Type Experimental
6.1.1. Administration
Participants will receive 1 dose of study  intervention at the vaccination visit (Day  1) in 
accordance with the study’s SoA. The study  intervention will be administered 
intramuscularl y by injecting the entire contents of the syringe (for 120 µg RSVpreF) or 
0.25 mL of a graduated sy ringe content (for 60 µgRSVpreF) into the deltoid muscle, 
preferabl y of the nondominant arm, unless medically contraindicated, in which case the 
injection may  be administered in the dominant arm. Study  intervention administration will be 
performed b y appropriately  designated stud y staff at the investigator site.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 42Standard vaccination practices must be observed, and vaccine must not be injected into blood 
vessels. Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction should be available in accordance with local guidelines for standard 
immunization practices.
Administration of study  interventions should be performed b y an appropriately  qualified, 
GCP -trained, and vaccine-experienced member of the study  staff (eg, ph ysician, nurse, 
physician ’s assistant, nurse practitioner , pharmacist, or medical assistant) as allowed by  local, 
state, and institutional guidance.
Study  intervention administration details will be recorded on the CRF .
6.1.2. Med ical Devices
In this stud y, medical devices being deplo yed are for the reconstitution diluent for the stud y 
intervention (RSVpreF or placebo). The stud y intervention supplies are provided in a kit that 
contains the study  intervention (RSVpreF or placebo ly ophilized powder in a vial), a PFS 
containing sterile water, and a vial adapter.
Instructions for medical device use are provided in the I PM.
All medical device deficiencies (including malfunction, use error, and inadequate labeling) 
shall be documented an d reported b y the investigator throughout the clinical investigation 
(seeSection 10.6) and appropriatel y managed b y the sponsor.
6.2.
Preparation , Handling , Storage , and Accountability
1.The investigator or designee must confirm that appropriate conditions
(eg, temperature) have been maintained during transit for all study  interventions 
received and an y discrepancies are reported and resolv ed before use of the study  
intervention.
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply , prepare, and/or administer study  intervention.
3.All study  interventions must be stored in a secure, en vironmentally  controlled, and 
monitored (manual or automated recording) area in accordance with the labeled 
storage conditions with access limited to the investigator and authorized site staff. At 
a minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperatures since previousl y documented upon 
return to business.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 434.Any excursions from the study  intervention label storage c onditions should be 
reported to Pfizer upon discovery  along with actions taken. The site should activel y 
pursue options for returning the study intervention to labeled storage conditions, as 
soon as possible. Once an excursion is identified, the study  intervention must be 
quarantined and not used until Pfizer provides permission to use the study  
intervention. Specific details regarding the excursion definition and information to 
report for each excursion will be provided to the site in the IPM.
5.Any storage conditions stated in the SRSD will be superseded b y the storage 
conditions stated on the label . See the IPM for storage conditions of the study  
intervention once reconstituted.
6.Study  interventions should be stored in their original containers.
7.The investig ator, institution, head of the medical institution (where applicable), 
orauthorized site staff is responsible for study  intervention accountability , 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final 
disposition records), such as the I PAL  or sponsor -approved equivalent. All study  
interventions will be accounted for using a stud y intervention accountability 
form/record.
8.Further guidance and information for the final disposition of unused study  
interventions are provided in the I PM. All destruction must be adequatel y 
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional poli cy, and any  special instructions 
provided b y Pfizer.
Upon identification of a product complaint, notify the sponsor within 1 business day  of 
discovery  as described in the I PM.
6.2.1. Preparation and Dispensing
See the IPM for instructions on how to prepare the study  intervention for administration. 
Study  intervention should be prepared and dispensed by  an appropriatel y qualified and 
experienced member of the study  staff (eg, physician, nurse, phy sician’s assistant, nurse 
practitioner, pharmacy  assistant/technici an, or pharmacist) as allowed b y local, state, and 
institutional guidance. A second staff member will verify  the dispensing.
Study intervention will be prepared by  qualified site personnel according to the I PM or 
package insert, and the study  intervention will be administered in an open -label manner.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 446.3.Assignment to Study Intervention
The study  intervention to be dispensed to the participant will be assigned using an IRT 
system. The site will utilize the I RT s ystem to assign the DU or container number(s) prio r to 
the start of study  intervention administration for each participant. The site will record the 
study  intervention assignment on the applicable CRF, if required.
Study  intervention will be dispensed at the study  visit (s)summarized in the SoA.
6.4.Blinding
6.4.1. Blinding of Participants
This is an open- label study . Participants and their caregivers will be unblinded to their 
assigned study intervention.
6.4.2. Blinding of Site Personnel
The study  is open -label, and all site personnel, including the investigator, investigator staff, 
and study  staff receiving, storing, dispensing, preparing, and administering the study  
interventions, will be unblinded.
Please refer to the IP Mfor further details.
6.4.3. Blinding of the Sponsor
To facilitate rapid review of d ata in real time, sponsor staff will be unblinded to study  
intervention allocation for the participants throughout the study .
6.4.4. Breaking the Blind
Not applicable. 
6.5. Study Intervention Compliance
When participants are dosed at the site, they  will receive study intervention directly  from 
theinvestigator or designee, under medical supervision. The date and time, as well as the 
anatomical location of each dose administered in the clinic, will be recorded in the source 
documents, and recorded in the CRF. The dose of study  intervention and study  participant 
identification will be confirmed at the time of dos e administration by a member of the study  
site staff other than the person administering the study  intervention.
6.6. Dose Modification
Not applicable.
6.7.Continued Access to Study Intervention A fter the End of the Study
No study  intervention will be provided to participants at the end of their study  participation. 
It is expected that participants will be treated as required with standard -of-care treatments, as 
advised b y their usual care physician.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 456.8.Treatment of Overdose
For this study , any  dose of study  intervention greater than 1 dose of study  intervention within 
a 24-hour time period will be considered an overdose.
In the event of an overdose, the investigator should:
1.Contact the study  medical monitor within 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs as medicall y appropriate and at 
least until the next scheduled follow -up.
3.Document the quantit y of the excess dose as well as the durat ion of the overdose in 
the CRF.
4.Overdose is reportable to Pfizer Safety  only when associated with an SAE .
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the study  medical monitor as needed base d on the clinical evaluation of the 
participant.
6.9.Prior and 
Concomitant Therapy
The following concomitant medications, vaccinations, and treatments will be recorded in the 
CRF:
Any vaccinations received from 28 day s prior to study  enrollment until the last study  
visit.
Prohibited medications and treatments listed in Section 6.9.1 if taken, will be 
recorded ,includ ingstart and stop dates, name of the medication, dose, unit, route, and 
frequency .
6.9.1. Prohibited Concomitant Vaccinations and Treatments
Receipt of an y nonstud y RSV vaccine at an y time prior to or during study 
participation.
Receipt of investigational or approv ed monoclonal antibodies against RSV within 
6months prior to or during stud y participation.
Investigational vaccines, drugs, or medical devices are prohibited during the course of 
the study . Note: COVID -19 vaccines authorized for temporary ,or emergency  use will 
not be prohibited during the course of this study  if administered more than 14 day s 
prior to study  intervention administration or at least 14 day s (from Day  15 onwards) 
after stud y intervention administration.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 46Receipt of blood/plasma products or immunoglobulin, from 28 day s before study  
intervention administration and thereafter during the course of the stud y
.
Nonstudy  vaccines may  not be given concomitantly with the study intervention or 
within 14 day s after study  intervention administration (Day  1through Day  14), except 
if medically  necessary  (eg, during an outbreak or pandemic situation).
Receipt of chronic s ystemic treatment with known immunosuppressant medications 
other than s ystemic corticosteroids meeting the criteria noted below, within 6 0 day s
of administration of study  intervention , through conclusion of the study .
Receipt of s ystemic corticosteroids (
≥20 mg/day  of prednisone or equivalent) for 
≥14days is prohibited from 28 day s prior to enrollment through D ay 28 after 
administration of st udy intervention ( Day1).
Prophy lactic antipy retics and other pain medication to prevent s ymptoms associated 
with study  intervention administration are not permitted. However, if a participant is 
taking a medication for another condition, even if it may  have antipy retic or 
pain- relieving properties, it should not be withheld prior to study  vaccination.
6.9.2. Permitted Concomitant Vaccinations and Treatments
Licensed vaccines may  be given during the study  starting 14 day s after study  
intervention administration (Day  15).
Inhaled/nebulized, intra -articular, intrabursal, or topical ( skin, ey es, or ears ) 
corticosteroids are permitted.
The use of antip yretics and other pain medication to treat sy mptoms associated with 
study  intervention administration is permitted du ring the participant’s participation in 
the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Since this is a single -dose study , this section is not applicable.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 477.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at their own request. Reasons for 
discontinuation from the study  include the following:
Refused further stud y procedures;
Lost to follow -up;
Death;
Study  termin ated b y sponsor;
AEs;
Participant request;
Investigator request;
Protocol deviation.
If a participant withdraws from the study , the participant’s parent(s)/legal guardian may  
request destruction of any  remaining samples taken and not tested, and the invest igator must 
document an y such requests in the site study  records and notify  the sponsor accordingl y.
A participant may discontinue from the study  procedure but continue to participa tein 
protocol -specified AE -monitoring activities as outlined in 
Section 1.3, as long as the 
participant or participant’s parent(s)/legal guardian does not withdraw consent.
If the participant’s parent(s)/legal guardian or a child who has provided assent during 
anyphase of the study  withdraws from the stud y and also withdraws consent/assent 
(Section 7.2.1) for disclosure of further information, no further evaluations will be performed 
and no additional data willbe collected. The sponsor may retain and continue to use an y data 
collected before such withdrawal of consent.
Lack of completion of all or an y ofthe withdrawal/earl
y-termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 487.2.1. Withdrawal of Consent
Participants who request ( or whose parent [s]/legal guardian requests) to discontinue receipt 
of study  intervention will remain in the study andmust continue to be followed for 
protocol -specified follow -up procedures. The only exception to this is when a participant or 
participant ’s parent(s)/legal guardian specificall y withdraws consent for any further contact 
with them or persons previously  authorized by  the participant or participant ’s parent(s)/legal 
guardian to provide this information. Participants or participants’ parent(s)/legal guardian s
should notify  the investigator in writing of the decision to withdraw consent from future 
follow -up, whenever possible. The withdrawal of consent should be explained in detail in the 
medical records b y the investigator , as to whether the withdrawal is onl y from further receipt 
of study  intervention or also from study  procedures and/or postvaccination study  follow -up 
andentered on the appropriate CRF page. In the event that vital status (whether the 
participant is alive or dead) is being measured, publicly  available information should be used 
to determine vital status only  as appropriately directed in accordance with local law .
7.3.Lost to Fol low-Up
A participant will be considered lost to follow -up if the participant repeatedly  fails to return 
for scheduled visits and the participant or participant’ s parent(s)/legal guardian is unable to 
be contacted b y the study site.
The following actions must be taken if a participant and participant’s parent(s)/legal guardian 
fail to attend a required study  visit:
The site must attempt to contact the participant’s parent(s)/legal guardian and 
reschedule the missed visit as soon as possible. Counsel the participant’s 
parent(s)/legal guardian on the importance of maintaining the assigned visit schedule, 
and ascertain whether the participant’s parent(s)/l egal guardian wishes for the 
participant to and/or whether the participant should continue in the study ;
Before a participant is deemed lost to follow
-up, the investigator or designee must 
make every  effort to regain contact with the participant’s parent(s)/legal guardian 
(where possible, 3 telephone calls and, if necessary , a certified letter to the 
participant’s last known mailing address or local equivalent methods). These contact 
attempts should be documented in the participant’s medical record ;
Should the participant’s parent(s)/legal guardian continue to be unreachable, the 
participant will be considered to have withdrawn from the study .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 498.STUDY ASSESSMENTS AND PROCEDURES
8.1.Administrative Procedures
The investigator (or an appropriate delegate at t he investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.
The date of birth will be collected to critically  evaluate the immune response and safety  
profile b y age.
Study  procedures and their timing are summar ized in the SoA. Protocol waivers or 
exemptions are not allowed.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, a s applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified crite ria and were performed 
within the time frame defined in the SoA.
Every ef fort should be made to ensure that protocol -required tests and procedures are 
completed as described. However , it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that they  have taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  man ner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for indivi dual participants in this study  is expected to be no 
more than 40 mL.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 508.1.1. Telehealth Visits
In the event that in -clinic study  visits cannot be conducted, every  effort should be made to 
follow up on the safet y of study participations at scheduled visits per the SoA or unscheduled 
visits.
Telehealth visits may  be used to assess participant safet y and collect data points. Telehealth 
includes the exchange of healthcare information and services via telecommunication 
technologies (eg, audio, video, videoconferencing software) remotel y, allowing the 
participant and the investigator to communicate on aspects of clinical care, including medical 
advice, reminders, education, and safet y monitoring. The following assessments must be 
performed during a telehealth visit (see the SoA):
Review and record an y AEs and SAEs since the last contact. Refer to Section 8.4.
Review and record an y new concomitant medications or changes in concomitant 
medications since the last contact.
Procedures as indicated for  unscheduled visits for fever or a G rade 3 or suspected 
Grade 4 reactions 
(Section 8.11).
Study  participants or participants’ parent(s)/legal guardians 
must be reminded to
promptly notify site staff about an y change in the participant’s health status.
8.2.Efficacy and/or Immunogenicity Assessments
8.2.1. Efficacy Assessments 
There are no efficacy  assessment sinthis study .
8.2.2. Immunogenicity Assessments
RSV serostatus will be determined for participants 2 to 5 years of ageprior to vaccination at 
Visit 1 .
Blood samples (approximately  5 mL per sample for children  10 years of age and 10mL 
forchildren 
10 to 18 yearsof age ) will be collected from participants for immunogenicit y 
testing at both V isit1 and Visit 3 (refer to Section 1.3, SoA). RSV A –and 
RSV B –neutralizing antibody  titers will be measured for each blood sample at each time 
point and reported as the NT s
.
Additionally , all participants will provide blood samples for PBMCs (approximately  1mL 
per year of age but no more than 10 mL)
,to be collected at both Visit 1 and Visit 3. PBMC 
samples will be used to characterize the cell -mediated immune response through measuring 
RSV Fantigen –specific CD4+ T cells secreting IFN andF antigen –specific CD4+ T cells 
secreting IL -4. Instructions for the collection and handling of biological samples will be 
provided in the laboratory manual.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 518.2.3. Biological Samples
Blood samples will be used onl y for scientific research. Each sample will be labeled with 
acode so that the laboratory  anal yst testing the samples will not know the participant’s 
identity, study  visit, or study  cohort associated with the sample. Samples that remain after 
performing assay s outlined in the protocol may be stored by  Pfizer. Unless a time limitation 
is required b y local regulations or ethical requirements, the samples will be stored for up to 
15 years after the end of the study  and then destroyed. If allowed by  the ICD, stored samples 
may be used for additional testing to better understand the immune responses to the 
vaccine(s) under study  in this protocol, to inform the development of other vaccines or 
vaccine -related products, and/or for vaccine -related assay  work suppo rting vaccine programs. 
No testing of the participant’s DNA will be performed using blood samples including those 
for PBMC isolation .
The participant orthe participant’s parent(s)/legal guardian 
may request that the participant’s
samples, if still identif iable, be destro yed at an y time; however, an y data alread y collected 
from those samples will still be used for this research. The biological samples may  be shared 
with other researchers as long as confidentiality  is maintained, and no testing of the 
partic ipant’s genetic material/DNA is performed.
8.3.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA. Unscheduled safet y 
measurements may  be obtained at any  time during the study  to assess any  perceive d safety  
issues.
A clinical assessment, including medical history , will be performed on all participants at their 
first visit to establish a baseline. Significant medical history  and observations from any  
physical examination will be documented in the CRF.
AEs and SAEs will be collected, recorded, and reported as defined in Section 8.4.
The participant will have his or her bod y temperature measured prior to each vaccination and 
will be observed for at least 30 minutes after vaccination. Any  acute reactions within the first 
30 minutes after administration of the study  intervention will be assessed and documented in 
the AE CRF.
Thesafet y parameters also include reactogenicit y e
-diary  reports of local reactions and 
systemic events (including fever) that occur in the 7 day s after administration of the study  
intervention. The e -diary  device will prompt the participant or the participa nt’s 
parent(s)/legal guardian to report these self -collected occurrences of local reactions and 
systemic events. These participant-reported local reactions and s ystemic events (including 
fever) are graded as described in Secti on 8.3.4.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 528.3.1. Physical Examinations
A phy sical examination will be performed at Visit 1. A brief phy sical examination will 
include, at a minimum, measurement of heig ht and weight, assessments of general 
appearance, lungs, cardiovascular s ystem, and l ymph node survey  as applicable.
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
Physical examination findings collected during the study  will be considered source data 
andwill not be required to be reported, unless otherwise noted. Any untoward ph ysical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 2 ) must be reported according to the processes in 
Section 8.4.1 to Section 8.4.3 .
8.3.2. Vital Signs
The participant ’s prevaccination temperature will be measured as per usual clinical practice.
Any untoward vital sign fin dings that are identified during the active collection period and 
meet the definition of an AE or SAE ( Appendix 2 ) must be reported according to the 
processes in Section 8.4.1 to Section 8.4.3.
8.3.3. Clinical Safe ty Laboratory Assessments
Clinical safety  laboratory assessments will not be collected in this study .
8.3.4. Reactogenicity Electronic Diary
The participant or participant’s parent(s)/legal guardian will be required to complete a 
reactogenicity  e-diary  after eac
h vaccination. These participants or participant s’ 
parent(s)/legal guardian swill be asked to monitor and record local reactions, sy stemic events ,
and temperature for 7 days from the day  of administration of the study  intervention. The 
reactogenicity  e-diary  allows recording of these assessments only  within a fixed time 
window, thus providing an accurate representation of the participant’s experience at that 
time. Data on local reactions and sy stemic events reported in the reactogenicity  e-diary  will 
be transferred electronically  to a third- party  vendor, where they  will be continually  available 
for review b y investigators, Pfizer clinicians, and other selected study  team members via an 
internet -based portal.
At intervals agreed to b y the vendor and Pfiz er, these data will be transferred electronicall y 
into Pfizer's database for anal ysis and reporting. These data do not need to be reported by  the 
investigator in the CRF as AEs.
Investigators (or designee) will be required to review the reactogenicity  e-diary data online at 
frequent intervals as part of the ongoing safet y review.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 53The investigator or designee must obtain stop dates from the participant or participant’s 
parent(s)/legal guardian for any  reactions ongoing on the last day  that the reactogenicit y
e-diary  was completed. The stop dates should be documented in the source documents and 
the information entered in the CRF.
Please note that all provisioned e- diary  devices must be collected at the end of Visit 3
(1-month follow -up visit ) pertheSoA.
8.3.4.1. Grading Scales
The grading scales used in this study  to assess local reactions and sy
stemic events as 
described below are derived from the FDA CBER guidelines on toxicity  grading scales for 
healthy  adult and adolescent volunteers enrolled in preventive vaccine clinical trials ,26with 
adaptations for applicability  to health y younger children.
8.3.4.2. Local Reactions
During the reactogenicit y e-diary  reporting period, participants or participants’ parents/legal 
guardians will be asked to assess re dness, swelling, and pain at the injection site and to 
record the sy mptoms in the reactogenicit y e-diary  daily  for 7 day s (Day s 1 through 7) after 
each vaccination. If a local reaction persists bey ond the end of the reactogenicity  e-diary  
period following vaccination, the participant or participant’s parent (s)/legal guardian will be 
requested to report that information. The investigator will enter this additional information in 
the CRF.
Participants will be provided with a measuring device. Redness and swelling will be 
measured and recorded in caliper units (measuring device units; range: 1to14 caliper units 
for participants ≥2 to 12 years of age and 1 to 21 caliper units forparticipants ≥12 to 
18years of age) for the first 7 days follow ing vaccination (Day s 1 through 7), and then 
categorized as absent, mild, moderate, or severe using the scale shown in Table 2.Measuring 
device units can be converte d to centimeters according to the following formula: 1 measuring 
device unit = 0.5 cm. Pain at the injection site will be 
assessed by theparticipants or 
participant s’ parent(s)/legal guardian s as absent, mild, moderate, or severe according to the 
grading scale in Table 2.
If a Grade 3 local reaction is reported in the reactogenicity  e-diary (
redness or swelling 
14caliper units for participants 12 years of age or  20 caliper units for participants 
≥12years of age ;Grade 3 pain at the injection site) , a telephone contact should occur to 
ascertain further details and determine whether a site visit is clinically  indicated. Onl y an 
investigator or medicall y qualified person is able to classify  a participant’s local reaction as 
Grade 4. If a participant experiences a confirmed Grade 4 local reaction, the investigator 
must immediately  notify  the sponsor and, if it is determined to be related to the 
administration of the s tudy intervention, further vaccinations (if applicable) will be 
discontinued in that participant.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 54Table 2. Local Reaction Grading Scale
Participant
AgeMild
(Grade 1)Moderate
(Grade 2)Severea
(Grade 3)Potentially 
Life-Threateningb
(Grade 4)
Pain at 
the 
injection 
site≥2 Years Does not 
interfere with 
activityInterferes with 
activityPrevents daily 
activityEmergency room visit or 
hospitalization for severe 
pain at the injection site
Redness ≥2 Yearsto
12 years1 to 4 caliper 
units (or 
measuring 
device units)
=0.5 to 2.0 cm5 to 14 caliper 
units (or 
measuring 
device unit s)
=>2.0 to 7.0 cm>14 caliper units 
(ormeasuring 
device unit s)
= >7 cmNecrosis or exfoliative 
dermatitis
≥12 Years 5 to 10 caliper 
units (or 
measuring 
device units)
=>2.0 to 5.0 cm11 to 20 caliper 
units (or 
measuring 
device units)
=>5.0 to 10.0 
cm>20 caliper units 
(or measuring 
device units)
=>10 cmNecrosis or exfoliative 
dermatitis
Swelling ≥2 Yearsto
12 years1 to 4 caliper 
units (or 
measuring 
device units)
=0.5 to 2.0 cm5 to 14 caliper 
units (or 
measuring 
device units)
=>2.0 to 7.0 cm>14 caliper units 
(or measuring 
device units)
=>7 cmNecrosis
≥12 Years 5 to 10 caliper 
units (measuring 
device units)
=>2.0 cm to 
5.0cm11 to 20 caliper 
units (measuring 
device units)
=>5.0 cm to 
10.0 cm>20 caliper units 
(ormeasuring 
device units)
=>10cmNecrosis
a.Parent(s)/legal guardians of participants 12 years of age experiencing local reactions 14 caliper units 
(7 cm) ,participants or parent(s)/legal guardians of participants ≥12 years of age experiencing local 
reactions 20 caliper units ( 10 cm) ,and parent(s)/legal guardians of participants experiencing Grade 3 
pain at the injection site are to be contacted by the study site. An unscheduled visit may be required.
b.Only an investigator or qualified designee is able to classify a participant’s local reaction as Grade 4, 
after clinical evaluation of the participant or documentation from another medically qualifie d source 
(eg,emergency room or hospital record). Grade 4 local reactions will be collected on the AE CRF and 
assessed by the investigator using the AE intensity grading scale as detailed in Section 10.2.3 .
8.3.4.3. Systemic Events
During the reactogenicit y e-diary  reporting period, participants or participants’ 
parent(s)/legal guardians will be asked to assess vomiting, diarrhea, headache, 
fatigue/tiredness, muscle pain, and joint pain and to record the s ymptoms in the 
reactogenicity  e-diary . The sy mptoms will be assessed by  the participant or participant’s 
parent(s)/legal guardian as absent, mild, moderate, or severe according to the grading scale 
inTable 3.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 55If a Grade 3 s ystemic event is reported in the reactogenicity  e-diary , a telephone contact 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated. Onl y an investigator or medicall y qualified person is able to classify a participant’s 
systemic event as Grade 4. If a participant experiences a confirmed Grade 4 systemic event, 
the investigator must immediately  notify  the sponsor and, if it is determined to be related to 
the administration of the study  intervention, further vaccinations (if applicable) will be 
discontinued in that participant.
Table 3. Systemic Event Grading Scale for Participants ≥2 Y ears of Age
Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially 
Life-Threatening 
(Grade 4)a
Vom iting 1-2 times in 
24hours>2 times in 24 hours Requires IV 
hydrationEmergency room 
visit or 
hospitalization for 
severe vomiting
Diarrhea 2 to 3 loose stools in 
24 hours4to 5 loose stools in 
24hours6 or more loose 
stools in 24 hoursEmergency room 
visit or 
hospitalization for 
severe diarrhea
Headache Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or
hospitalization for 
severe headache
Fatigue/tiredness Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or 
hospitalization for 
severe 
fatigue /tiredness
Muscle pain Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or 
hospitalization for 
severe muscle pain
Joint pain Does not interfere 
with activitySome interference 
with activityPrevents daily 
routine activityEmergency room 
visit or 
hospitalization for 
severe joint pain
a.Only an investigator or qualified designee is able to classify a participant’s systemic event as Grade 4, 
after clinical evaluation of the participant or documentation from another medically qualified source 
(eg,emergency room or hospital record). Grade 4 local reactions will be collected on the AE CRF and 
assessed by the investigator using the AE intensity grading scale as detailed in Section 10.2.3 .
8.3.4.4. Fever
In order to record information on fever, a thermometer will be given to participants with 
instructions on how to measure oral temperature at home. Temperature will be collected in 
the reactogenicit y e-diary in the evening dail y during the reactogenicit y e-diary  reporting 
period. It will also be collected at an y time during the reactogenicit y e-diary data collection 
periods when fever is suspected. Fever is defined as an oral temperature ≥38.0°C (100.4°F). 
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 56The highest temperature for each day  will be recorded in the reactogenicit y e-diary . 
Temperature will be measured and recorded to 1 decimal place. Temperatures recorded 
indegrees Fahrenheit will be programmatically converted to degrees Celsius and the n 
categorized according to the scale shown in Table 4during anal ysis.
If a fever of ≥39.0°C ( ≥102.1°F) is reported in the reactogenicity  e-diary , a telephone contact 
should occur to ascertain further details and determine whether a site visit is clinically  
indicated. Onl y an investigator or medicall y qualified person is able to confirm a 
participant’s fever as 40.0°C ( 104.0°F). If a participant experiences a confirme d fever 
40.0°C ( 104.0 °F), the investigator must immediately  notify  the sponsor and, if it is 
determined to be related to the administration of the study  intervention, further vaccinations 
(if applicable) will be discontinued in that participant.
Table 4. Scale for Fever
≥38.0-38.4°C (100.4 -101.1 °F)
38.4-38.9°C (101.2 -102.0 °F)
38.9-40.0°C (102.1 -104.0 °F)
40.0°C (104.0 °F)
8.3.5. Stopping Rules
The following stopping rules apply  by age group and are in place for all participants, based 
on review of AE data and e -diary  reactogenicit y data, through 30days after the 
administration of study  intervention in each age group. These data will be monitored on an 
ongoing basis b y the investigator (or medicall y qualified designee) and sponsor in order to 
promptly  identify  and flag an y event that potentially  contributes to a stopping rule.
The sponsor study  team will be unblinded d uring the study , so they  will be able to assess 
whether or not a stopping rule has been met on the basis of a participant’s individual study  
intervention allocation.
In the event that sponsor personnel confirm that a stopping rule is met, the following act ions 
will commence:
The I RC will review all appropriate data.
The stopping rule will PAUSE randomization and study  intervention administration 
for all dose levels in the impacted age group.
For all participants vaccinated, all other routine study  conduct a ctivities, including 
ongoing data entry , reporting of AEs, participant reactogenicity  e
-diary  completion, 
blood sample collection, and participant follow -up, will continue during the pause.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 57A stopping rule is met if any  of the following rules occur after a dministration of RSVpreF. 
Reactogenicit y e-diary  data confirmed by  the investigator as being entered by  the participant 
in error will not contribute toward a stopping rule.
The RSVpreF dose levels within an age group will contribute to stopping rules colle ctivel y; 
vaccine candidate dose levels will contribute to stopping rules together.
Stopping Rule Criteria:
1.If any participant vaccinated with RSVpreF at an y dose level develops an SAE that is 
assessed b y the investigator as possibly related, or for which there is no alternative, 
plausible, attributable cause.
2.If any participant vaccinated with RSVpreF at an y dose level develops a Grade 4 
local reaction or s ystemic event after vaccination ( Section 8.3.4) that is assessed as 
possibly  related by  the investigator, or for which there is no alternative, plausible, 
attributable cause.
3.If any participant vaccinated with RSVpreF at an y dose lev
el develops a fever 
40.0°C ( 104.0 °F) for at least 1 daily  measurement after vaccination (see
Section 8.3.4.4) that is assessed as possibly  related by  the investigator, or for which 
there is no alternative, plausible, attributable cause.
4.If any 2 participants vaccinated with RSVpreF at any  dose level within the same age 
group report the same or similar severe (Grade 3) AE after vacci nation that is
assessed as possibl y related by the investigator, or for which there is no alternative, 
plausible, attributable cause. Note that the local reactions, sy stemic events, and fever 
specified in 
Section 8.3.4 reported within 7 day s of (Day  1 through Day  7) 
administration of the study  intervention, irrespective of whether they  are recorded in 
the e -diary  or as A Es, are excluded from this stopping rule.
5.If there is a n ICU admission or participant death that is assessed b y the investigator to 
be attributed to RSV infection, all available clinical and preclinical data should be 
reviewed to evaluate for RSV vaccine –elicited ERD .
8.3.6. Randomization and Vaccination After a Stopping Rule Is Met 
Once the IRC ha sreviewed the safety  data and provided guidance, a notification will be sent 
from the sponsor to the sites with guidance on how to proceed.
8.4.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE 
and an SAE can be found in Appendix 2.
The definitions of device
-related safet y events (ADEs and SADEs) can be found in 
Section 10.6. Device deficiencies are covered in Section 8.4.9.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 58AEs may  arise from s ymptoms or other complaints reported to the investigator by  the 
participant (or , when appropriate, by  a caregiver , surrogate, or the participant's legall y 
authorized r epresentative), or they  may  arise from clinical findings of the investigator or 
other healthcare providers (clinical signs, test results, etc).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events th at meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  (see Section 7.1 ).
During the active collection period as described in Section 8.4.1, each participant’ s 
parent(s)/legal guardian/legally  authorized representative will be questioned about the 
occurrence of AEs in a nonleading manner .
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“ active collection 
period”) for each participant begins from the time the participant’s parent (s)/legal guardian
provides informed consent, which is obtained before the participant ’s participation in the 
study  (ie, before undergoing an y stud y-relate d procedure and/or receiving study  
intervention ),through and including Visit 3. In addition, AEs occurring up to 48 hours after 
blood draws  that are related to study  procedures must be reported in the CRF.
SAEs , AESI s
,and NDCMCs will be collected from the time the participant ’s parent(s)/legal 
guardian provides informed consent through the duration of the study .
Follow -up by  the investigator continues throughout the active collection period and until the 
AE or SAE or its sequelae resolve or stabilize at a level acceptable to the investigator.
When a clinically  important AE remains ongoing at the end of the active collection period, 
follow -up by  the investigator continues until the AE or SAE or its sequelae resolve or 
stabilize at a level acceptable to the investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study  and also withd raws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently  discontinues or temporaril y discontinues from the study  because 
of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using 
the V accine SAE Report ingForm.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 59Investigators are not obligated to activel y seek information on AEs or SAEs after the 
participant has concluded study  participation. However , if the investigator learns of any  SAE, 
including a death, at an y time after a participant has completed the study , and they  consider 
the event to be reasonably related to the stud y intervention, the investigator must promptly  
report the SAE to Pfizer using the Vaccine SAE Report ingForm .
8.4.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in
Section 8.4.1 are reported to Pfizer Safety  on the Vaccine SAE Report ingForm immed iately 
upon aware ness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 2. The investigator will submit any updated SAE data to the sponsor within 
24hours of its being available .
8.4.1.2.
Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent a s described in Section 8.4.1 , will be recorded 
on the AE section of the CRF .
The investigator is to record on the CRF all directly  observed, and all spontaneously  reported 
AEs and SAEs reported by  the participant.
As part of ongoing safet y reviews conducted b y the sponsor, an y nonserious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE. To a ssist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.4.2. Method of Detecting AEs and SAEs
The method of recording, eva luating, and assessing causality  of AEsand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 2.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant or participant’s parent(s)/legal guardian is 
the preferred method to inquire about AEoccurrences.
8.4.3. Follow -
Up of AEs and SAEs
After the initial AEor SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 60In general, follow -up information will include a description of the event in suf ficient detail 
toallow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of availa ble 
autopsy  findings must be submitted as soon as possible to Pfizer Safety .
Further information on follow -up procedures is provided in Appendix 2.
8.4.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of 
astudy  intervention under clinical investigation are met.
The sponsor has a legal responsibil ity to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.
The sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to th e regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSAR sor other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD (s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact with or exposure to the study  intervention. Such exposure 
may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed . 
Anenvironmental exp osure may include EDP, EDB ,and occupational exposure .
Any such exposures to the study  interventio nunder study  are reportable to Pfizer Safety  
within 24 hours of investigator awareness.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 618.4.5.1. Exposure During Pregnancy
An EDP  occurs if:
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention.
A male participant who is receiving or has discontinued study  intervention 
inseminates a female partner .
A female nonparticipant is found to be pregnant while being exposed or having been 
exposed to study  intervention because of environmental exposure. Below are 
examples of environmental EDP :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  inadvertent product 
administration via needlestick or skin c ontact.
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  inadvertent product administration via needlestick or skin contact
then inseminates his female partner prior to or around the time of conception .
The inve stigator must report EDP  to Pfizer Safety within 24 hours of the investigator ’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy).
If EDP occurs 
in aparticipant/participant’s partner , the investigator must report this 
information to Pfizer Safety  on the Vaccine SAE Report ingForm and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Detai ls of the 
pregnancy  will be collected after the start of study  intervention and until the 
participant’s last visit of the study .
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety  using the Vac cine SAE Report ingForm and EDP 
Supplemental Form. Since the exposure information does not pertain to the 
participant enrolled in the study , the information is not recorded on a CRF; however, 
a cop y of the completed Vaccine SAE Report ingForm is maintained in the 
investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP  reports with an unknown outcome. The investigator will follow the pregnancy until 
completion (or until preg nancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP  Supplemental F orm. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, 
thereason(s) for termination should be specified and, if clinically  possible, the structural 
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 62integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findi ngs are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows:
Spontaneous abortion includ ingmiscarriage and missed abortion should be reported 
as an SAE ;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention.
Additional information regarding the EDP  may  be requested by  the sponsor . Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Preg nant Partner Release of Information Form to provide to his 
partner .
8.4.5.2. Exposure During Breastfeeding
An EDB occurs if:
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female nonparticipant is found to be breastfeeding while being exposed or having 
been exposed to study  intervention (ie, environmental exposure). An example of 
environmental EDB is a female famil y member or healthcare provider who reports 
that she is breastfeeding after having been exposed to the study  intervention by
injection or skin contact .
The investigator must report EDB to Pfizer Safety  within 24 hours of the investigator ’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using the Vaccine SAE Report ingForm. When EDB occurs in the setting of environmental 
exposure, the exposure information does not pertain to the participant enrolled in the study , 
so the information is not recorded on a CRF . However , a copy  of the completed Vaccine SAE 
Report ingForm is maintained in the investigator site file.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 63An EDB report is not created when a Pfizer drug specificall y approved for use in 
breastfeeding women (eg, vitamins) is administered in accord ance with authorized use. 
However , if the infant e xperiences an SAE associated with such a drug, the SAE is reported 
together with the EDB .
8.4.5.3. Occupational Exposure
The investigator must report any  instance of occupational exposure to Pfizer Safet y within 
24hours of the investigator ’s awareness
using the Vaccine SAE Report ingForm , regardless 
of whether there is an associated SAE. Since the information about the occupational exposure
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however , a copy  of the completed Vaccine SAE Report ingForm must be maintained in 
the investigator site file.
8.4.6. Cardiovascular and Death Events
Not applicable.
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.4.8. Adverse Events of Special Interest
Diagnosis of Guillain- Barrésyndrome
Diagnosis of acute pol yneuropath y without an underlying etiology
Diagnosis of atrial fibrillation
Preterm delivery  (delivery  at <37 0/7 weeks’ gestation)
Diagnosis of a h ypertensive disorder of pregnanc y
Details of the AESIs listed above are further defined in the investigator site file.
AESI sare examined as part of routine safet y data review procedures throughout the clinical 
trial and as part of signal detection processes. Should an aggregate analysis indicate that 
these prespecified events occur more frequentl y than expected, eg, based on epidemiological 
data, literature, or other data, then this will be submitted and reported in accordance with 
Pfizer’s safet y reporting requirements. Aggregate anal yses of safet y data will be performed 
on a regular basis per internal SOPs. 
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 64All AESI s mu st be reported as an AE or SAE following the procedures described in 
Sections 8.4.1 through Section 8.4.4 . An AESI is to be recorded as an AE or SAE on the 
CRF. I n addition, an AESI  that is also an SAE must be reported via PSSA or using the 
Vaccine SAE Report ingForm. The active collection period for AESIs is from the signing of 
the ICD until the end of the study  for all participants.
8.4.8.1. Lack of Efficacy
This section is not applicable for this study , as efficacy  is yet to be demonstrated in the study  
population.
8.4.9. Medical Device Deficiencies
Medical devices being provided for use in this study
are those listed in Section 6.1.2. In order 
to fulfill regulatory  reporting obligations worldwide, the investigator isresponsible for the 
detection and documentation of events meeting the definitions of device deficiency that occur 
during the stud y with such devices.
The def inition of a 
medical device deficiency can be found in Appendix 6.
Note: AEs and/or SAEs that are associated with a medical device deficiency  will follow the 
same processes as other AEs or SAEs, as outlined in Section 8.4.1 throu gh Section 8.4.4 and 
Appendix 2of the protocol.
8.4.9.1. Time Period for Detecting Medical Device Deficiencies
Medical device deficiencies that result in an incident will be detected, documented, and 
reported during all periods of the study
 in which the medical device is used.
Importantly , reportable device deficiencies are not limited to problems with the device itself 
but also include incorrect or improper use of the device and even intentional misuse, etc.
If the investigator learns of any  device deficiency at an y time after a participant has been 
discharged from the study , and such 
deficiency is considered reasonably  related to a medical 
device provided for the study , the investigator will promptly  notify  the sponsor .
The method of documenting medical device deficiencies is provided in Section 10.6.
8.4.9.2. Follow -
Up of Medical Device Deficiencies
Follow -upapplies to all participants, including those who discontinue study  intervention.
The investigato ris responsible for ensuring that follow -up includes an y supplemental 
investigations as indicated to elucidate the nature and/or causality  of the deficiency .
New or updated information will be recorded on a follow -upform with all changes signed 
and dated b y the investigato r.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 658.4.9.3. Prompt Reporting of Device Deficiencies to the Sponsor
When a device deficiency  occurs:
1.The investigator notifies the sponsor by a contact method asdetailed in the I PM
within 1 business day  of determining that the incident meets the protocol definition of 
a medical device deficiency .
2.The device deficiency  must be recorded on the Medical Device Complaint form.
3. If an AE (either serious or nonserious) associated with the device deficiency occurs, 
then the AE must be entered into the AE section of the CRF .
4.If an SAE associated with the device deficiency  is brought to the attention of the 
investigator, the investigator must immediately  notify  Pfizer Safet y of the SAE 
(see Section 8.4.1.1). All rel evant details related to the role of the device in the event 
must be included in the Vaccine SAE Reporting Form as outlined in Section 8.4.1.1
and Section 8.4.1.2.
The sponsor will be the contact for the rece
ipt of device deficiency  information .
8.4.9.4. Regulatory Reporting Requirements for Device Deficiencies
The investigator will promptly  report all device deficiencies occurring with any  medical 
device provided for use in the study
 in order for the sponsor to fulfill the legal responsibility  
to notify  appropriate regulatory  authorities and other entities about certain safet y information 
relating to medical devices being used in clinical studies.
Theinvestigator , or responsible person according to local requirements (eg, the head of the 
medical institution), will comply  with the applicable local regulatory  requirements relating to 
the reporting of device deficiencies to the IRB/EC.
8.4.10. Vaccination Errors
Vaccination errors may  result from the administration or consumption of the study  
intervention by  the wrong participant, or at the wrong time, or at the wrong dosage strength.
Vaccination errors are recorded and reported as f ollows :
Recorded on the 
Vaccination Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the Vaccine 
SAE Report ingForm to 
Pfizer Safety Within 
24 Hours of Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the vaccination errorOnly  if associated with an 
SAE
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 66Vaccination errors include:
1.Vaccination errors involving participant exposure to the study  intervention;
2.Potential vaccination errors or uses outside of what is foreseen in the protocol that do or 
do not involve the study  participant ;
3.The administration of expired study  intervention;
4.The administration of an incorrect study  intervention;
5.The administration of an incorrect dosage;
6.The administration by  an incorrect route;
7.The administration of study  intervention that has undergone temperature excursion from 
the specified storage range, unless it is determined by  the sponsor that the study  
intervention under question is acceptable f or use.
Such vaccination errors occurring to a stud y participant are to be captured on the vaccination
error page of the CRF , which is a specific version of the AE page.
Whether or not the vaccination error is accompanied by  an AE, as determined by  the 
investigator , the vaccination error is recorded on the vaccination error page of the CRF and, 
if applicable, an y associated AE(s), serious and nonserious, are recorded on the AE page of 
the CRF .
In the event of a vaccination dosing error , the sponsor should b e notified within 24 hours.
Vaccination errors should be reported to Pfizer Safety  within 24 hours on a Vaccine SAE 
Report ingForm only when associated with an SAE .
8.5.Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study .
8.6.Genetics
8.6.1. Specified Genetics
Specified g enetic anal yses are not evaluated in this study .
8.7.Biomarkers
Biomarkers are not evaluated in this study .
8.8.Immunogenicity Assessments
Immunogenicity assessments are described in Section 8.2.2.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 678.9.Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study .
8.10. Study Procedures
8.10.1. Visit 1 – Screening and Vaccination Visit (Clinic; Day 1)
Voluntary , written, study -
specific informed consent (from the participant’s parent[s] /legal 
guardian), and assent (from the participant, where appropriate), will be obtained before 
enrollment and before any study -related procedures are performed. Each signature on the 
ICD must be personall y dated b y the signatory. The investigator or his or her designee 
willalso sign the ICD. A copy  of the signed and dated ICD must be given to the 
participant/participant’s p arent(s)/legal guardian. The source data must reflect that the 
informed consent (and assent if appropriate) was obtained before participation in the study .
It is anticipated that the procedures below will be conducted in a stepwise manner; ensure 
that proc edures listed prior to administration of the investigational vaccine are conducted 
prior to study  vaccination. If screening and vaccination arenot on the same day , all 
procedures listed as “on the day  of and prior to vaccination” must beconducted prior t o 
vaccination and on the day  of the vaccination.
Assign a single participant number using the IRT sy stem.
Obtain the participant’s demograph y (including date of birth, sex, race, and ethnicity). 
The full date of birth will be collected to criticall y evalua te the immune response and 
safet y profile b y age.
Obtain the participant’s medical history of clinical significance.
On the day  of and prior to vaccination, perform a phy sical examination, including, at a 
minimum, measurement of height and weight, assessme nts of general appearance, lungs, 
cardiovascular s ystem, and ly mph node survey .
For participants 2 to 5 years of age: This procedure must be repeated on the day  of 
and prior to vaccination if serostatus results will not be available on the same day  as 
vaccination.
On the day  of and prior to vaccination, measure the participant’s temperature as per usual 
clinical practice .
For participants 2 to 5 years of age: This procedure must be repeated on the day  of 
and prior to vaccination if serostatus results w ill not be available on the same day  as 
vaccination .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 68All eligible participants will proceed to complete the vaccination visit.
Record nonstud y vaccinations as described in Section 6.9.
Obtain details of
prohibited medication used as described in Section 6.9.1 .
On the day  of and prior to vaccination, ensure and document that all of the inclusion 
criteria and none of the exclusion criteria are met.
On the day  of and prior to vaccination, ensure that the participant meets none of the 
temporary  delay  criteria as described in Section 5.5.
On the day  of and prior to vaccination, collect a blood sample (approximately  5 mL for 
children 
10 years of age and approximately  10 mL for children 10 to  18 yearsof age ) 
for immunogenicity .
On the day  of and prior to vaccination, collect a blood sample for PBMC isolation.
On the day  of and 
prior to vaccination, c hildren 2 to 5 years of age will have RSV 
serostatus tested .
Note: Participants 2 to 5 years of age who are seropositive can be enrolled and 
administered RSVpreF on Day 1.All participants 5 y ears of age and older will be 
considere d RSV seropositive and will not require a screening test.
On the day  of and prior to vaccination, obtain the participant’s randomization number and 
study  intervention allocation using the IRT s ystem. Refer to the IRT manual for further 
instructions on this process.
Qualified site staff member(s) will administer a single dose of 
study  intervention into the 
deltoid muscle of the (preferabl y) nondominant arm, unless medically contraindicated, in 
which case the injection may  be administered in the dominant arm. Please refer to the 
IPMfor further instruction on this procedure.
Site staff must observe the participant for at least 30 minutes after study  intervention 
administration for an y acute reactions. Record an y acute reactions (including time of 
onset) in the participant’s source documents and on the AE page of the CRF, and on an 
SAE form as applicable.
Explain the e -diary  technologies available for this study  (see Section 8.3.4) and assist the 
participant’s parent(s)/legal guardian in downloading the stud y application onto his or her 
own device or issue a provisioned device if required.
Issue a measuring 
device to measure local reactions at the injection site and a 
thermometer for recording daily temperatures and provide instructions on their use.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 69Provide instructions on reactogenicity  e-diary  completion and ask the participant’s 
parent(s)/legal guardian to complete the reactogen icity e-diary  from Day 1 through 
Day 7, with Day 1 being the day  of vaccination.
Ask the participant’s parent(s)/legal guardian, as appropriate, to contact the site staff or 
investigator immediatel y if the participant experiences an y of the following from Day 1 
through Day  7 after vaccination (where Day  1 is the day  of vaccination) to determine if 
an unscheduled reactogenicity  visit is required:
Fever ≥39.0°C ( 102.1°F).
Redness or swelling at the injection site 14 caliper units (or 7 cm) for children 
12years old and/or 
20caliper units (or 10cm)for children ≥ 12 years old.
Grade 3 pain at the injection site.
Any severe s ystemic event.
If the participant doesn’t call, the site should contact the participant to determine if an 
unscheduled reactogenicit y visit is required.
Record AEs, SAEs ,AESIs ,and NDCMCs as described in Section 8.4.
Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator 
immediately  if a medically  attended event (eg ,doctor’s visit, emergency  room visit) 
orhospitalization occurs.
Schedule an appointment for the participant ’snext study  visit.
Complete the source documents.
The in
vestigator or an authorized designee completes the CRFs and the 
dispenser/administrator completes the study  intervention accountability  records.
The investigator or appropriately  qualified designee reviews the reactogenicity  e-diary  
data online following v accination to evaluate participant compliance and as part of the 
ongoing safet y review. Daily review is optimal during the active diary period.
8.10.2. Visit 2 – 1-Week Follow- Up Visit ( Telehealth ;6 to 8 Days After Vaccination on
Day 1)
Contact the participant’s parent(s)/legal guardian by  telephone.
Obtain details of an y nonstudy  vaccinations and prohibited concomitant medications and 
treatments as described in Section 6.9.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 70Review the participant’s reactogenicity  e-diary  data. Collect stop dates of any  
reactogenicity  e-diary  events ongoing on the last day  that the reactogenicity  e-diary  was 
completed and record stop dates in the CRF if required.
Record AEs, SAEs, AESIs ,and NDCMCs as described in Section 8.4.
Schedule an appointment for the participant ’snext study  visit.
Remind the participant’s parent(s)/legal guardian to bring the e -diary  to the next visit.
Complete the source documents.
The investigator or an authorized designee completes the CRFs.
8.10.3.
Visit 3 – 1- Month Follow - Up Visit (Clinic ;28 to 35 Days After Visit 1)
Obtain details of an y nonstudy  vaccinations and prohibited concomitant medications and 
treatments as described in Section 6.9.
Collect a blood sample (approximately  5 mL for children 10 years of age and 
approximately  10 mL for children 10 to  18 yearsof age ) for immunogenicity .
Collect 
a blood sample for PBMC isolation.
Review ongoing reactogenicity  e-diary  symptoms reported as present on the last day  of 
the e -diary  and obtain stop dates. R ecord stop dates in the CRF if required.
Record AEs, SAEs, AESIs ,and NDCMCs as described in Section 8.4.
Ask the participant’s parent(s)/legal guardian to contact the site staff or investigator if a 
medically  attended event (eg, doctor’s visit, emergency  room visit) or hospitalization 
occurs.
Colle ct the participant’s e
-diary  or assist the participant with removing the study  
application from his or her own personal device (if this has not been done alread y).
Schedule an appointment for the participant for the next study  visit.
Complete the source do cuments.
The investigator or an authorized designee completes the CRFs.
8.10.4. Visit 4 – 6- Month Follow - Up Visit ( Telehealth ; 175 to 189 Days After Visit 1)
Contact the participant’s parent(s)/legal guardian by  telephone.
Obtain details of an y nonstudy  vaccinations as detailed in Section 6.9.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 71Record details of an y of the prohibited medications specified in Section 6.9.1 . Review 
ongoing reactogenicity  e-diary  symptoms reported as present on the last day  of the 
e-diary  and obtain stop dates. R ecord stop dates in the CRF if required.
Record SAEs ,AESIs ,and NDCMCs as described in Section 8.4.
Complete the source documents.
The investigator or an authorized designee completes the CRFs.
8.11. Unscheduled Visit for Fever or a Grade 3 or Suspected Grade 4 Reaction
If a participant or participant’s parent (s)/legal guardian reports redness or swelling 
14caliper units (or 7cm) for participants 12 years of age and  20 caliper units 
(or 10 cm) for participants ≥12 years of age or a Grade 3 local reaction ( Table 2), an y 
Grade 3 systemic event ( Table 
3), or fever  39.0°C (102.1°F) (Table 4) in the reactogenicit y 
e
-diary , a telephone contact should occur to ascertain further details and determine whether a 
site visit is clinically  indicated. If suspected Grade 4 local reaction ( Table 2 ), systemic event 
(Table 3), or fever  40.0 ° C (104.0°F) (Table 4) is reported in the reactogenicity  e-diary , a 
telephone contact or site visit should occur to confirm whether the event meets the criteria for 
Grade 4. A site visit must be scheduled as soon as possible to assess the participant unless 
any of the following is true:
The participant is unable to attend the unscheduled visit.
The local reaction/s ystemic event is no longer present at the time of the telephone 
contact.
The participant or participant’s parent(s)/legal guardian recorded an incorrect value in the 
reactogenicity  e-diary  (confirmation of a reactogenicity  e-diary  data entry  error).
The PI  or authorized designee determined it was not needed.
This telephone contact (or site visit) will be recorded in the participant’s source 
documentation and th e CRF.
If the participant is unable to attend the unscheduled visit, or the PI  or authorized designee 
determined it was not needed, an y ongoing local reactions/sy stemic events must be assessed 
at the next study  visit.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 72During the unscheduled visit, the reactions should be assessed b y the investigator or a 
medically  qualified member of the study  staff such as a study  physician or a study  nurse, as 
applicable to the investigator’s local practice, who will:
Measure bod y temperature ( °F/°C).
Measure minimum and maximum diameters of redness (if present).
Measure minimum and maximum diameters of swelling (if present).
Assess injection site pain (if present) in accordance with the grades provided in Table 
2.
Assess sy stemic events (if present) in accordance with the grades provided in Table 
3.
Assess for other findings associated with the reaction and record on the AE page of the 
CRF, if appropriate.
The investigator or an authorized designee will complete the unscheduled visit 
assessment page of the CRF.
8.12. Communication and Use of Technology
In a study  of this nature that requires illness events to be reported outside of scheduled study  
visits, it is vital that communication between the study  site and the participant or participant’ s 
parent(s)/legal guardian is maintained so that safety events or endpoint events are not missed. 
This study  will employ  various methods, tailored to the individual participant, to ensure that 
communication is maintained, and study  information can be transmitted securely . Using 
appropriate technology , such as a study  application, a communication pathway  between the 
participant or participant’s parent(s)/legal guardian and the study  site staff will be 
established. The participant or participant’s parent(s)/l egal guardian may  be able to utilize his 
or her own device to access this technology , or use a device provided b y the sponsor. 
Traditional methods of telephone communication will also be available. The technology  
solution may  facilitate the following:
An a lert in the event that the participant is hospitalized.
Visit reminders.
Messages of thanks and encouragement from the study  team.
A platform for recording local reactions and s ystemic events (e- diary ). See Section 8.3.4.
If a participant or participant’s parent(s)/legal guardian is not activel y completing the 
reactogenicity  e-diary , the investigator or designee is required to conta ct the participant or 
participant’s parent(s)/legal guardian to ascertain the reason and also to obtain details of an y 
missed events.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 739.STATISTICAL CONSIDERATIONS
Methodology for summary  and statistical anal yses of the data collected in this study  is 
describ ed here and further detailed in the SAP, which will be maintained by the sponsor. 
The SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be re flected in a 
protocol amendment.
9.1.Statistical Hypothesis
There is no statistical h ypothesis testing in this study .
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Enrolled All participants who have a signed ICD.
Randomized population All enrolled participants who are assigned a randomization 
number in the I RT sy stem.
Safety  population All enrolled participants who receive the stud y intervention.
Defined Analysis Set Description
Evaluable immunogenicity  
populationThis population will be defined asall participants who meet 
the following criteria:
Are eligible for the study;
Receive the intervention;
Have the 1- month postvaccination blood collection within 
an appropriate window;
Have at least 1 valid and determinate assay  result 1 month 
after vaccination;
Have no major protocol violations from vaccination 
through the 1 -month postvaccination blood draw .
mITT immunogenicit y 
populationAll participants who arerandomized and ha veat least 1 valid 
and determinate assay  result at any  time point after receiving 
study  intervention.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 749.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are performed and will 
describe the anal yses and pro cedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary andsecondary  
endpoints.
9.3.1. General C onsiderations
CIs for all endpoints in the statistical anal ysis will be presented as 2-sided at the 95% level 
unless specified otherwise.
The safet y analyses are based on the safet y population. Participants will be summarized by  
vaccine group according to the study  interventions they  actuall y received. Missing AE dates 
will be imputed a ccording to Pfizer safety  rules. Completely  missing e -diary  data (ie, all 
7days of e -diary  collection were missing) will not be imputed. For partially complete e -diary  
data (ie, 1- 6 day s of reactogenicity  data are available), it is expected that these mis sing 
e-diary  days would be queried by  the investigator, and an y missed reported reactogenicity 
would be entered in the AE CRF; therefore, the primary  anal ysis will use the reactogenicit y 
recorded in the AE CRF to impute the partially  missed e -diary  data to estimate the
reactogenicity  rates during the 7- day period .
For all the immunogenicity  endpoints, the analy sis will be based on the evaluable 
immunogenicit y population .An additional anal ysis will be performed based on the mI TT 
population if there is a lar ge enough difference in sample size between the mI TT population 
and the evaluable immunogenicity  population. 
9.3.1.1. Analyses for Binary Data
Descriptive statistics for categorical variables (eg, proportions) are the percentage (%) and
the numerator (n) and the d enominator (N) used in the percentage calculation. 
The exact 95% CI for binary  endpoints for each group will be computed using the 
Fdistribution (Clopper -Pearson).27
9.3.1.2. Analyses for Continuous Data
Unless otherwise stated, descriptive statistics for continuous variables are n, mean, median, 
SD, minimum, and maximum.
9.3.1.2.1. Geometric Means
Continuous immunogenicity  endpoints will be logarithmically  transformed for anal ysis. 
Geometric means and associated 2 -sided 95% CIs will be derived b y calculating group 
means and CIs on the natural log scale based on the t distribution, and then exponentiating 
the results.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 759.3.1.2.2. Geometric Mean Fold Rises
GMFRs will be calculated as the group mean of the difference of logarithmically  transformed 
assay  results (later time point min us earlier time point) and exponentiating the mean. GMFRs 
are limited to participants with nonmissing values at both time points. The associated 2 -sided 
95% CI s will be obtained by  constructing CIs using the Student t distribution for the mean 
difference o
n the logarithm scale and exponentiating the confidence limits.
9.3.1.2.3. Reverse Cumulative Distribution Curves
Empirical RCDCs will plot proportions of participants with values equal to or exceeding a 
specified assay  value versus the indicated assay  value, for all observed assay  values. Data 
points will be joined by  a step function with the line first going down and then to the right to 
the next assay  value.
9.3.2. Primary Endpoint(s) /Estimand(s) Analysis
Table 5. Primary Endpoint Analyses
Endpoint Statistical Analysis Methods
Safety Descriptive statistics will be provided for each reactogenicity  endpoint 
for each RSVpreF dose level within each age stratum. L ocal reactions 
(redness, swelling, and pain at the injection site) and sy stemic events 
(fever, fatigue/tiredness, headache, vomiting, diarrhea, muscle pain, and 
joint pain) from Day  1 through Day  7 after vaccination will be presented 
by maximum severity  and any severit y. Descriptive summar y statistics 
will include counts and percentages of participants with the indicated 
endpoint and the associated Clopper -Pearson 95% CI  (Section 9.3.1.1 ).
AEs and SAEs will be categorized according to MedDRA terms. All of 
the AEs within 1 month and SAE s/NDCMCs throug hout the study  will 
be descriptivel y summarized with counts, percentages, and associated 
Clopper -Pearson 95% CI sfor each RSVpreF dose level within each age 
stratum ( Section 9.3.1.1).
Descriptive summaries may  also be pro
vided for the combined age 
group (2 to  18years) within the same RSVpreF dose level.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 769.3.3. Secondary Endpoint(s) /Estimand(s) Analysis
Table 6.Secondary Endpoint Analyses
Endpoint Statistical Analysis Methods
Immunogenicit yGMTs before vaccination and 1 month after vaccination will be 
descriptivel y summarized with 2- sided 95% CI sfor each RSVpreF 
dose level within each age stratum for both RSV A and RSV B 
subgroup NTs (Section 9.3.1.2.1 ).
GMFRs from before vaccination to 1 month after vaccination will be 
descriptivel y summarized with 2
-sided 95% CI sfor each RSVpreF 
dose level within each age stratum for both RSV A and RSV B 
subgroup NTs (Section 9.3.1.2.2 ).
GMTs, GMFRs ,and associated 95% C Is may  also be descriptivel y 
summarized for the combined age group (2 to 18 years) for each 
RSVpreF dose level for both RSV A and RSV B subgroup NTs
.
Thefrequency  of CD4+ T cells expressing IFN andthefrequency  of
CD4+ T cells expressing IL -4 before vaccination and 1 month after 
vaccination will be descriptively  summarized .
9.4.Interim Analyses
No interim anal ysis is planned.
9.4.1. Analysis Timing
As Phase 1 is open- label, the sponsor may  conduct reviews of the data during the study  for 
the purpose of decision making.
One final analy sis will be performed when all data are cleaned.
9.5.Sample Size Determination
Phase 1 enrollment is not based on a statistical criterion.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 7710. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws.
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg, advertisements) must be 
reviewed and approved by  the sponsor ,submitted to an I RB/EC 
by the investigator, and reviewed and approved by  the IRB/EC before the study  is in itiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and any substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies, European MDR 2017/745 for clinical device research, 
and all other applicable local regulations .
10.1.1.1. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authority in any area of the world, or if the investigator is awa re of any  new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immediately .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 78In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study  participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of 
the ICH GCP  guidelines that the investigator 
becomes aware of.
10.1.2.
Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent /Assent Process
The investigator or their representative will explain the nature of the study  to the 
participant andtheir parent(s)/legal guardian and answer all questions regarding the 
study .The participant andtheir parent(s)/legal guardian should be given sufficient time 
andopportunity  to ask questions and to decide whether or not to participate in the trial.
When consent is obtained from a participant’s parent(s)/legal guardian, the participant’s 
assent (affirmative agreement) must be subsequently  obtained when the participant has the 
capac ity to provide assent, as determined by  the IRB/EC. If the investigator determines that a 
participant’s decisional capacit y is so limited, they cannot reasonabl y be consulted, then, as 
permitted by  the IRB/EC and consistent with local regulatory  and legal requirements, the 
participant’s assent may  be waived with source documentation of the reason assent was not 
obtained. If the study participant does not provide their own assent, the source documents 
must record wh y the participant did not provide assent (for example, the child is not of 
assenting age per local regulations or policies), how the investigator determined that the 
person signing the consent was the partici pant’s parent(s)/legal guardian, the consent signer’s 
relationship to the study  participant, and that the participant’s assent was obtained or 
waived. If assent is obtained verball y,itmust be documented in the source documents.
If study  participants are minors who reach the age of majorit y or if a child reaches the age of 
assent (per local IRB/EC requirements) during the study , as recognized under local law, the 
child or adolescent must then provide the appropriate assent or consent to document their
willingness to continue in the study . For an adolescent who reaches the age of consent, 
parental consent would no longer be valid. If the enrollment of emancipated minors is 
permitted bythe IRB/EC and local law, the participant must provide documentation of l egal 
status to give consent without the permission of a legally  authorized representative.
Participants and their parent(s)/legal guardian s must be informed that their participation is 
voluntary .The participant’s parent(s)/legal guardian will be required to sign a statement of 
informed consent thatmeets the requirements of 21 CFR 50, local regulations, I CH 
guidelines, HI PAA requirements, where applicable, and the IRB/EC or study  center.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 79The investigator must ensure that each study  participant’s parent(s)/ legal guardian and the 
study  participant ,as applicable ,are full y informed about the nature and objectives of the 
study , the sharing of data related to the study , and possible risks associated with 
participation, including the risks associated with the pr ocessing of the participant’s personal 
data.
The participant’s parent(s)/legal guardian must be informed that the participant’s personal 
study -related data will be used by  the sponsor in accordance with local data protection 
law. The level of disclosure mu st also be explained to the participant’s parent(s)/legal 
guardian.
The participant’s parent(s)/legal guardian must be informed that the participant’s medical 
records may  be examined by  Clinical Qualit y Assurance auditors or other authorized 
personnel appointed by  the sponsor, by  appropriate I RB/EC members, and by  inspectors 
from regulatory  authorities.
The investigator further must ensure that each study  participant’s parent(s)/legal guardian is 
fully  informed about their right to access and correct their child’s personal data and to 
withdraw consent for the processing of their child’s personal data ,keeping in mind the 
privacy  rights that may  restrict access of older adolescents’ medical records by their 
parent(s)/legal guardian sin certain regions
.
Thesource documentation must include a statement that written informed consent, and as 
applicable, assent, was obtained before the participant was enrolled in the study  and the date 
the written consent/assent was obtained. The authorized person obtaining the informed 
consent must also sign the I CD.
Parent(s)/legal guardian and the participant must be reconsented to the most current version 
of the I CD(s)/assent during their participation in the study as required per local regulations .
A cop y of the ICD(s) and ass
ent, if written, must be provided to theparent(s)/legal 
guardian and the participant.
If participants are rescreened, the participants’ parent(s)/legal guardian s orthe participants,
where appropriate, are required to sign a new ICD/assent (as applicable) .
10.1.3.1. Electronic Consent 
Participants may  be able to experience the informed consent process by  electronic means 
(eConsent). The eConsent process includes an electronic presentation of the informed 
consent document (eICD), clinical trial educational components (as applicable), and 
electronic signatures (if allowed by  local regulations). The use of eConsent does not replace 
or alter the ICD content or informed consent process as described above. The eConsent 
process complies with applicable regulations and spon sor policies to ensure reliability  and 
data privacy .  
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 8010.1.3.2. Remote Consent 
Participants may  be able to experience the informed consent process at their location rather 
than in person at the site. There are 2 types of remote consent, both of which involve the 
participant not being ph ysically present with the study  investigator or delegated site staff: 
(1) obtaining consent with the active participation of a PIor delegated site staff during the 
consenting process; and (2) obtaining consent without the active participation of a PIor 
delegated site staff, such as a via a healthcare website or portal.
10.1.4. Data Protection
All parties will comply  with all applicable la ws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants
’ personal data will be stored at the study  site in encry pted electronic and/or paper
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The stud y site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster . In the event of a potential personal data breach, the study  site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  law.
To protect the rights and freedoms of participa ntswith regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names wil l not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant- specific code. The study site will 
maintain a confidential list of participant s who participated in the study , linking each 
participant ’s numerical code to their actual identity and medical record ID. In case of data 
transfer , the sponsor will protect the confidentiality  of participant s’ personal data consistent 
with the c linical study agreement and applicable privacy  laws.
Information technology  systems used to collect, process, and store study -related data are 
secured b y technical and organizational securit y measures designed to protect such data 
against accidental or unlawful loss, alteration, or unauthorized disclosure or access.
The sponsor maintains SOPs on how to respond in the event of unauthorized access, use, or 
disclosure of sponsor information or sy stems.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 8110.1.5. Committees Structure
10.1.5.1. Data Monitoring Committee
This study  will use an IRC. The IRCis independent of the study  team and includes only  
internal (IRC) members. The IRCcharter describes the role of the IRC in more detail .
The responsibility  of the IRC will include at a minimum:
Review of safet y data in the case of a stopping rule being met.
Review of safet y data accumulated for up to 7 day s following vaccination of the 
5-to 18-year age group to make a recommendation for commencing dos e 
administration in the 2- to 5-year age group.
Review of safet y data accumulated for up to 7 day s following vaccination of the 
2-to 5-year age group to make a recommendation for dose escalation.
Review of safet y and immunogenicit y data accumulated from 7 day s following 
vaccination of both the 2- to 5-yearand 5 -to 18-year age groups to make a 
recom mendation for dose selection for Phase 2/3.
Review of safet y and immunogenicit y data accumulated for 1 month following 
vaccination.
The IRC
will be responsible for ongoing monitoring of the safet y of participants in the study  
according to the charter . The recommendations made b y the IRC will be forwarded to the 
appropriate authorized Pfizer personnel for revie wandfinal decision. Pfizer will 
communicate such decisions, which may  inclu de summaries of aggregate analy ses of safet y 
data, to regulatory  authorities and investigators
,as appropriate.
10.1.6. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of s tudies on www .clinicaltrials.gov (ClinicalT rials.gov), the EudraCT /CTI S, and/or 
www .pfizer .com, and other public registries and websites in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirem ents of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was c onducted.
www.clinicaltrials.gov
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 82Pfizer posts clinical trial results on www .clinicaltrials.gov for Pfizer -sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or ef ficacy  of a product, 
regardless of the geographical locatio n in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  US law.
EudraCT /CTI S
Pfizer posts clinical trial r esults on EudraCT /CTI Sfor Pfizer -sponsored interventional studies 
in accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts CSR synopses and plain- language study  results summaries on www .pfizer .com 
for Pfizer -sponsored interventional studies at the same time the corresponding stud y results 
areposted to www.clinicaltrials.gov. CSR sy nopses will have personally  identif iable 
information anon ymized.
Documents within marketing applications
Pfizer complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary  documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally  identifiable information anony mized.
Data sharing
Pfizer provides researchers secure access to participant -level data or full CSRs for the 
purposes of “ bona -fide scientific research ” that contribute sto the scientific understanding 
ofthe disease, target, or compound class. Pfizer will make data from thes e trials available 
18months after study  completion. Participant -level data will be anon ymized in accordance 
with applicable privacy  laws and regulations. CSRs will have personall y identifiable 
information anon ymized.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investiga tor is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF .
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 83The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties .
QTL s are predefined parameters that are monitored during the study .Important deviations 
from the QTLs and any remedial actions taken will be summarized in the CSR.
The investigator must permit study -related monitoring, audits, IRB/EC review , and 
regulatory  agency  inspections and provide direct access to source records an ddocuments .
This verification may  also occur after study  completion. I t is important that the 
investigator(s) and their relevant personnel are available during the monitoring visits and 
possible 
audits, or inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study -critical data items and 
processes (eg, risk- based initiatives in operations and quality  such as risk management and 
mitigation strategies and anal ytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and 
monitoring plan maintained and util ized by  the sponsor or designee.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor . No records may  be 
transferred to another location or part y without written notification to the sponsor .The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investiga tor will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify thesponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the ins pection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant ’s medical records. The investigator will promptly  
provide copies of the inspection findings to the sponso r or its agent. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 8410.1.8. Source Documents
Source documents provide evidenc e for the existence of the participant and substantiate 
theintegrit y of the data collected. Source document s are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must 
be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending 
onthe study . Also, current medical records must be available.
Definition of what constitutes a source docume nt, and its origin can be found in the Source 
Document Locator , which is maintained by  the sponsor .
Description of the use of the computerized sy stem is documented in the data management 
plan, which is maintained by  the sponsor .
The investigator must maintain accurate documentation (source record
) that supports the 
information entered in the CRF .
The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by authorized site personnel are accurate, com plete, and verifiable from source documents; 
that the safet y and rights of participants are being protected; and that the study is being 
conducted in accordance with the currentl y approved protocol and an y other study  
agreements, I CH GCP guidelines, and al l applicable regulatory  requirements.
10.1.9. Use of Medical Records
In certain situations, sponsor review of redacted copies of participant medical records for 
SAE reporting may  be performed, where ethicall y and scientificall y justified and permitted 
by local reg ulations, to ensure participant safet y. 
Due to the potential for a participant to be reidentified from their medical records, the 
following actions must be taken when medical records are sent to the sponsor or sponsor 
designee:
The investigator or site staff must redact personal information from the medical 
record. The personal information includes, but is not limited to, the following: 
participant names or initials , participant dates (eg, birthdate, date of hospital 
admission/di scharge, date of death), participant identification numbers (eg, Social 
Security  number, health insurance number, medical record number, 
hospital/institution identifier), p articipant location information (eg, street address, 
city, country , postal code, I P address), participant contact information
(eg, telephone/fax number, email address ).
Each medical record must be transmitted to the sponsor or sponsor designee using 
systems with technical and organizational security  measures to ensure the protection 
of personal data (eg, Florence is the preferred s ystem if available). 
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 85There may  be unplanned situations where the sponsor may  request medical records (eg, 
sharing medical records so that the sponsor can provide study -related advice to the 
investigator). The medical records should be submitted according to the procedure 
described above.
10.1.10. Study and Site Start and Closure
The study  start date is the date of the first participant’s first visit .
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor , incl uding (but not limited to) 
regulatory  authorit y decision, change in opinion of the I RB/EC, or change in benefit -risk 
assessment .Study  sites will be closed upon study completion. A study  site is considered 
closed when all required documents and study  supplies have been collected and a stud y-site 
closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to thesponsor 
or designee/ CRO if requested to do so by  the responsible I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local healt h authorities, the sponsor ’s procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the E Cs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  
of
the reason for termination or suspension, as specified b y the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol ,the contract will control as to termination rights.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 8610.1.11. Publication Policy
For multicenter trials, the primary  publication will be a joint publication developed b y the 
investigator and Pfizer reporting the primary  endpoint(s) of t he study  covering all study  sites. 
The investigator agrees to refer to the primary  publication in any  subsequent publications. 
Pfizer will not provide any financial compensation for the investigator’s participation in the 
preparation of the primary congres s abstract, poster, presentation, or primary  manuscript for 
the study .
Investigators are free to publish individual center results that they  deem to be clinically  
meaningful after publication of the overall results of the study  or 12 months after primary  
completion date or stud y completion at all sites, whichever occurs first, subject to the other 
requirements described in this section.
The investigator will provide Pfizer an opportunity  to review any  proposed publication or 
any other t ype of disclosure of the study  results (collectively , “publication”) before it is 
submitted or otherwise disclosed and will submit all publications to Pfizer 30 days before 
submission. If an y patent action is required to protect intellectual propert y rights, the 
investigator a grees to delay  the disclosure for a period not to exceed an additional 60 day s 
upon request from Pfizer. This allows Pfizer to protect proprietary  information and to provide 
comments, and the investigator will, on request, remove an y previousl y undisclosed
confidential information before disclosure, except for an y stud y-intervention or Pfizer -related 
information necessary  for the appropriate scientific presentation or understanding of the 
study  results. For joint publications, should there be disagreement r egarding interpretation 
and/or presentation of specific anal ysis results, resolution of, and responsibility  for, such 
disagreements will be the collective responsibility  of all authors of the publication.
For all publications relating to the stud y, the inv estigator and Pfizer will comply  with 
recognized ethical standards concerning publications and authorship, including those 
established by  the International Committee of Medical Journal Editors. The investigator will 
disclose an y relationship with Pfizer an d any  relevant potential conflicts of interest, including 
any financial or personal relationship with Pfizer, in any  publications. All authors will have 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication .
10.1.12. Sponsor’s 
Medically Qualified Individual
The contact information for the sponsor ’s MQI for the study  is documented in the study  
contact list located in the supporting stud y documentation/study  portal or other electronic 
system .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 87To facilitate access to their investigator and the sponsor ’s MQI for study -related medical 
questions or problems from nonstudy  healthcare professionals , participants are provided with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study  intervention identifiers, (b) participant’ s study  identification number , (c) site 
emergency phone number active 24 hours/day , 7 day s per week, and (d) Pfizer C all C enter 
number .
The ECC is intended to augment, not replace, the establ ished communication pathway s 
between the participant and their investigator andsite staf f, and between the investigator and 
sponsor study  team. The ECC is only to be used by  healthcare professionals not involved in 
the research study , as a means of reaching the investigator or site staf f related to the care of a 
participant. The Pfizer Call Center number is to be used when the investigator and site staff 
are unav ailable .The Pfizer Call Center number is not for use by  the participant directl y; if a 
participant calls that number directly , they will be directed back to the investigator site.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 8810.2. Appendix 2: Adverse Events: Definitions and Procedures for Recording, 
Eval uating, Follow
-Up, and Reporting
10.2.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study  intervention, whether or not considered 
related to the stud y intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator. Any abnormal laboratory test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms.
Requires additional diagnostic testing or medical/surgical in tervention .
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including an 
increase in either frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or th e clinical sequelae of a suspected drug- drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 89Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur ( social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.2.2. Definition of an SAE
AnSAE is defined as any untoward med ical occurrence that, at any dose , meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing ho spitalization
In general, hospitalization signifies that the participant has been admitted (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospitalization are A Es.If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or w as necessary , the 
AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 90d.Results in persistent or significant disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle), thatmay interfere with or prevent every day 
life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a Pfizer product of an infectious a gent, pathogenic 
or nonpathogenic
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a Pfizer product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exer cised by the investigator in deciding 
whether SAE reporting is appropriate in other situations, such as significant medical 
events that may  jeopardize the participant or may  require medical or surgical 
intervention to prevent one of the other outcomes list ed in the above definition. These 
events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency  or 
drug abuse.
10.2.3. Recording/Reporting and Follow -Up of A Esand/or SAE sDuring the Active 
Colle ction Period
AE and SAE Recording /Reporting
The table below summarizes the requirements f or recording A Eson the CRF and for 
reporting SAE son the Vaccine SAE Report ingForm to Pfizer Safety throughout the active 
collection period . These requirements are delineated for 3 types of events: (1) SAEs; (2) 
nonserious A Es; and (3) exposure to the study  intervention under stud y during pregnancy  
or breastfeeding, and occupational exposure.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 91It should be noted that the Vaccine SAE Report ingForm for reporting of SAE information 
is not the same as the AE page of the CRF. When the same data are collected, the forms 
must be completed in a consistent manner. A Esshould be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the Vaccine SAE 
Report ingForm for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the Vaccine
SAE Report ingForm to 
Pfizer Safety Within 
24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding All AEs or SAEs associated 
with EDP or EDB
Note: I nstances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRFAll instances of EDP are 
reported (whether or not 
there is an associated SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE)**
Environmental or 
occupational exposure to 
the product under stud y to 
a nonparticipant (not 
involving EDP or EDB)None. Exposure to a study 
nonparticipant is not 
collected on the CRFThe exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to Pfizer 
Safety using the Vaccine SAE Report ingForm  and EDP Supplemental Form; if the EDP is associated 
with an SAE, then the SAE is reported to Pfizer Safety using the Vaccine SAE Report ingForm .
**EDB is reported to Pfizer Safety using the Vaccine SAE Report ingForm ,which woul d also include 
details of any SAE that might be associated w ith the EDB.
***Environmental or occupational exposure: AEs or SAEs associated with occupational exposure are 
reported to Pfizer Safety using the Vaccine SAE Report ingForm .
When an AE or SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnostic reports) 
related to the event.
The investigator will then record all relevant AE or SAE information in the CRF .
It is notacceptable for the investigator to send photocopies of the participant’s medical 
records to Pfizer Safety  in lieu of completion of the Vaccine SAE Report ingForm /AE
or SAE CRF page.
There may  be instances when copies of medical records for cert ain cases are requested 
by Pfizer Safet y.In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to Pfizer Safety .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 92The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories:
GRADE If required on the AE page of the CRF, the investigator will use the 
adjectives MILD, MODERATE, SEVERE, or LIFE- THREATENING to 
describe the maximum intensity  of the AE. For purposes of consistency , 
these intensity  grades are defined as follows:
1 MILD Does not interfere with participant ’s usual 
function.
2 MODERATE Interferes to some extent with participant ’s usual 
function.
3 SEVERE Interferes significantl y with participant ’s usual 
function.
4 LIFE -THREATENING Life-threatening consequences; urgent 
intervention indicated.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention and 
each occurrence of each AE or SAE. The investigator will use clinical judgment to 
determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in their assessment.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 93For each AE or SAE, the investigator must document in the medical notes that they 
have reviewed the AE or SAE and have provided an assessment of causality.
There may  be situations in which an SAE has occurred, and the investigator has 
minimal information to include in the initial report to the sponsor . However, it is very 
important that the investigator always make an assessment of causality for every 
event before the initial transmission of the SAE data to the sponsor .
The investigator may  change their opinion of causality  in light of follow -up 
information and send a nSAE follow -up report with the updated causality  assessment.
The causality  asse ssment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting
purposes, as defined b y the sponsor . In addition, if the investigator determines that an 
SAE is associated with study  procedures, the investigator must record this causal 
relationship in the source documents and CRF, and report such an assessment in the 
dedicated section of the Vaccine SAE Report ingForm and in accordance with the SAE 
reporting requirements.
Follow -Up of A Esand SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  the 
sponsor ,to elucidate the nature and/or causalit y of the AE or SAE as full y as possible.
This may  include additional laboratory  tests or investigations, histopathological 
examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator will provide Pfizer Safety  with a cop y of an y postmortem 
findings ,including histopathology .
New or updated information will be recorded in the originally  submitted documents .
The investigator will submit any  updated SAE data to the sponsor within 24 ho urs of 
receipt of the information.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 9410.2.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic DCT
The primary  mechanism for reporting an SAE to Pfizer Safety will be the electronic 
DCT .
If the electronic s ystem is unavailable, then the site will use the paper SAE DCT
(seenext section) to report the event within 24 hours.
The site will enter the SAE data into the electronic DCT (eg, eSAE or PSSA) or paper 
form (as applicable) as soon as t he data become available.
After the stud y is completed at a given site, the electronic DCT will be taken off -line to 
prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives up dated 
data on a previously  reported SAE after the electronic DCT has been taken off- line, 
then the site can report this information on a paper SAE form (see next section) or to 
Pfizer Safety  by telephone.
SAE Reporting to Pfizer Safety via the Vaccine SAE Report ingForm
Facsimile transmission of the Vaccine SAE Report ingForm is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the fac simile is not working , an alternative method should be 
used, eg, secured (Transport Lay er Securit y) or password -protected email. If none of 
these methods can be used, notification by  telephone is acceptable with a copy  of the 
Vaccine SAE 
Report ingForm sent b y overnight mail or courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Vaccine SAE Report ingForm pages within the designated 
reporting time frames.
10.3. Appendix 3: Contraceptive and Barrier Guidance
Not applicable.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 9510.4. Appendix 4: Liver Safety: Suggested Actions and Follow - Up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators, ” while those who show transient liver injury  but adapt 
are termed “adaptors ”.In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
“suscept ible”to progressive and serious liver injury , commonly  referred to as DILI. 
Participant s who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “ susceptible ”.
LFTs are not required as a routine safety  monitoring procedure in this study . However , should 
an investigator deem it necessary  to assess LFT s because a participant presents with clinical 
signs/sy mptoms, such LFT  results should be managed and followed as d escribed below .
In the majority  of DILI cases, elevations in AST and/or ALT precede T bili elevations 
(2 × ULN) b y several day s or weeks. The increase in T
bili ty picall y occurs while AST/AL T 
is/are still elevated above 3 × ULN (ie, AST/AL T and T bili va lues will be elevated within 
the same lab oratory sample). In rare instances, by the time T
bili elevations are detected, 
AST/AL T values might have decreased. 
This occurrence is still regarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR ALT in addition to T bili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have b een excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. 
Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy
’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and T bili baseline values within the normal range who 
subsequently  present with AST OR AL T values ≥3 × ULN AND a T bili value 
≥
2 ×ULN with no evidence of hemol ysis and an alkaline phosphatase value 
2 ×ULN or not available.
For participant s with baseline AST OR ALT OR T bili values above the ULN, the 
following threshold values are used in the definition mentioned ab ove, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values 
≥2times the baseline values AND ≥3 ×ULN; or ≥8 × ULN (whichever is 
smaller).
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 96Preexisting values of T bili above the normal range: T bili level increased from 
baseline value b y an amount of 
≥1 × ULN or if the value reaches ≥3 × ULN 
(whichever is smaller).
Rises in AST/AL T and T bili separated by more than a few weeks should be assessed 
individually  based on clinical judgment; an y case where uncertainty  remains as to whether 
itrepresents a potential Hy
’s law case should be reviewed with the sponsor .
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y with in 48 hours from awareness of the abnormal results. This evaluation should 
include laboratory  tests, detailed history , and ph ysical assessment.
In addition to repeating measurements of AST and ALT and T bilifor suspected Hy ’s law
cases , additional laborat ory tests should include albumin, CK, direct and indirect bilirubin, 
GGT , PT/I NR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  itself or a s a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history , history  of contact 
with a jaundiced person, sur gery, blood transfusion
, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample sfor acetamino phen /paracetamol drug and/or protein adduct levels may  be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
T
bili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other 
reason for the LFT  abnormalities has y et been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potentia l DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 9710.5. Appendix 5: Kidney Safety Monitoring Guidelines
10.5.1.
Laboratory Assessment of Change in Kidney Function and Detection of Kidney 
Injury
Standard kidney  safety  monitoring requires assessment of baseline and postbaseline serum 
creatinine (Scr measurement to eGFR [Scr- based eGFR ]or [eCrCl ]). Baseline and 
postbaseline Scy s makes it feasible to distinguish AKI from other causes of Scr increase. If 
Scr increase is confirmed after baseline, then reflex measurement of Scy s is indicated to 
estimate the combined Scr -Scys eGFR calculation (for adults onl y).
Regardless of whether kidney  function monitoring tests a re required as a routine safet y 
monitoring procedure in the study , if the investigator or sponsor deems it necessary  to further 
assess kidney  safety  and quantify  kidney  function, then these test results should be managed 
and followed per standard of care.
10.5.2. Age-Specific Kidney Function Calculation Recommendations
10.5.2.1. Adolescents (12 Y ears to <18 Years) —Cockcroft -Gault Formula
CrCl (mL /min)
Males: Cr/Cl = [(140 -age) ×
body  weight (in kg)] / [Scr (in mg/dL ) × 72]
Females: Cr/Cl = 0.85 ×[(140 -age) × body  weight (in kg)] / [Scr (in mg/dL) × 72]
10.5.2.2. Children (2 Years to <12 Y ears) —Modified Schwartz Equation
CrCl normalized to BSA (mL /min/1.73 m2) = (K × Ht) / Scr
Ht in centimeters; Scr in mg/dL.
K (proportionality  constant): Female child <12 y ears: K = 0.55.
Male child <12 y ears: K = 0.70.
10.5.3. Adverse Event Grading for Kidney Safety Lab oratory Abnormalities
AEgrading for decline in kidney  function (ie, eGFR or eCrCl) will be according to KDIGO
criteria.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 9810.6. Appendix 6: A Es , ADEs, SAEs, SADEs, USADEs, and Device Deficiencies:
Definition sand Procedures for Recording, Evaluating, Follow -Up, and Reporting in 
Medical Device Studies
Definitions of a Medical Device Deficiency
The definitions and procedures detailed in this appendix are in accordance with I SO 14155
and the European MDR 2017/745 for clinical device research (if applicable) .
Both the investigator and the sponsor will comply  with all local reporting requirements for 
medical devices.
The detection and documentation procedures described in this pr otocol apply to all sponsor 
medical devices provided for use in the stud y (see Section 6.1.2 for the list of sponsor 
medical devices).
10.6.1. Definition of AE and ADE
AE and ADE Definition
An AE is defined in Appendix 2 (Section 10.2.1 ).
An ADE is defined as an AErelated to the use of an investigational medical device. 
This definition includes any  AEsresulting from insufficient or inadequate instructions 
for use, deplo yment, implantation, installation, or operation, or any  malfunction of the 
investigational medical device as well as an y event resulting from use error or from 
intentional misuse of the investigational medical device.
10.6.2. Definition of SAE, SADE ,and USADE
SAE Definition
An SAE is defined in Appendix 2 (Section 10.2.2 ).
SADE Definition
ASADE is defined as an ADE that has resulted in any  of the consequences 
characteristic of an SAE .
Any device deficiency  that might have led to an SAE if appropriate ac tion had not been 
taken, intervention had not occurred, or circumstances had been less fortunate.
USADE Definition
A USADE (also identified as UADE in US Regulations 21 CFR 813.3) is a SADE that
by its nature, incidence, severit y, or outcome has not been identified in the current 
version of the risk analy sis management file .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 9910.6.3. Definition of Device Deficiency
Device Deficiency Definition
A device deficiency  is an inadequacy  of a medical device with respect to its identity , 
quality , durabilit y, reliability , safet y, or performance. Device deficiencies include 
malfunctions, use errors, and inadequate information supplied by  the manufacturer .
10.6.4. Recording/Reporting and Follow -Upof Medical Device Deficiencies
Device Deficiency Recording
When a device deficiency  occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant device deficiency  information in the 
participant’s medical records, in accordance with the investigator’s normal clinical 
practice , and will also capture the required information on the Medical Device 
Complaint f
orm.
It is notacceptable for the investigator to send photocopies of the participant’s medical 
records to 
Pfizer Safety in lieu of following the reporting process described in the
Medical Device Complaint form.
There may  be instances when copies of medical records for certain cases are requested 
by Pfizer Safet y. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to Pfizer Safety .
If the investigator determines that the medical device deficiency  may  have injured the 
participant (ie, the medical device deficiency  is associated with an AE or SAE), then 
the investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis will be 
documented in the participant’s medical record and recorded as the AE or SAE rather 
than the individual signs/sy mptoms. Requirements for recor ding and reporting an AE
or SAE are provided in Appendix 2(Section 10.2.3).
For device deficiencies, it is very  important that the investigator describes any  
corrective or remedial actions taken to prevent recurrence of the incident .
A remedial action is an y action other than routine maintenance or servicing of a 
medical device wh ere such action is necessary  to prevent recurrence of a device 
deficiency . This includes any  amendment to the device design to prevent 
recurrence.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 100Assessment of Causality Occu rring in Conjuncti on With a Medical Device Deficiency
If an AE or SAE has occurred in conjunction with a medical device deficiency , the 
investigator must assess the relationship between each occurrence of the AE or SAE 
and the medical device deficiency . The investigator will use clinical judgment to 
determine the relationship.
A “reasonable possibility” of a relationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products ,in their assessm ent.
For each device deficiency , the investigator must document in the medical notes that 
they have reviewed the device deficiency  and ha veprovided an assessment of 
causality .
There may  be situations in which an SAE has occurred, and the investigator has 
minimal information to include in the initial report to the sponsor . However, it is very  
important that the investigator alway s make an assessment of causality  for every  event 
before the initial transmission of the SAE data to the sponsor.
The investigator may change their opinion of causality  in light of follow -up 
information and send a nSAE follow -up report with the updated causality  assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -Up of Medical Device Deficiency
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  the 
sponsor to elucidate the nature and/or causalit y of the device deficiency  as fully  as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
New or updated informa tion regarding the nature of the device deficiency  will be 
recorded in the originall y completed Medical Device Complaint f orm.
New or updated information regarding an y SAE that was potentially associated with 
the medical device deficiency will be submitted to Pfizer Safety  on the Vaccine SAE 
Report ingForm within 24 hours of receipt of the information, according to the 
requirements provided in Appendix 2 .
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 10110.6.5. Reporting of SAEs
Reporting of an SAE to Pfizer Safety  must be performed according to the processes 
described in Appendix 2(Section 10.2.4 ).
10.6.6. Reporting of SADEs
SADE Reporting to Pfizer Safety
Note: There are additional reporting obligations for medical device deficiencies that are 
potentially  related to SAEs (ie , aSADE) that must fulfill the legal responsibility  to notify  
appropriate regulatory  authorities and other entities about certain safet y information 
relating to medical devices being used in clinical studies.
Any device deficiency  that is associated with an SAE must be reported to the sponsor 
within 24 hours after the investigator determines that the eve nt meets the definition of a 
device deficiency .
The sponsor shall review all device deficiencies and determine and document in 
writing whether they  could have led to an SAE. These shall be reported to the 
regulatory  authorities and I RBs/E Csas required by  national regulations.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 10210.7. Appendix 7: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
ADE adverse device effect
AE adverse event
AESI adverse event of special interest
AKI acute kidney  injury
Al(OH) 3 aluminum hy droxide
ALT alanine aminotransferase
AST aspartate aminotransferase
AxMP auxiliary  medicinal product
BSA body  surface area
CBER Center for Biologics Evaluation and Research (United States)
CDC Centers for Disease Control and Prevention (United States)
CFR Code of Federal Regulations (United States)
CHF congestive heart failure
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CONSORT Consolidated Standards of Reporting Trials
COPD chronic obstructive pulmonary  disease
COVID -19 coronavirus disease 2019
CRF case report form
CRO contract research organization
CSR clinical study  report
CT clinical trial
CTIS Clinical Trial I nformation Sy stem
DCT data collection tool
DILI drug-induced liver injury
DNA deox yribonucleic acid
DU dispensable unit
EC ethics committee
ECC emergency  contact card
ECG electrocardiogram
eCrCl estimated creatinine clearance
eCRF electronic case report form
EDB exposure during breastfeeding
e-diary electronic diary
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
eICD electronic informed consent document
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 103Abbreviation Term
EMEA European Medicines Agency
ERD enhanced respiratory  disease
eSAE electronic serious adverse event
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration (United States)
FIH first-in-human
FI-RSV formalin -inactivated respiratory  syncytial virus vaccine
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GMFR geometric mean fold rise
GMR geometric mean ratio
GMT geometric mean titer
HIPAA Health Insurance Portability  and Accountability  Act
Ht height
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ICU intensive care unit
ID identification
IFN interferon 
IL-4 interleukin -4
IMP investigational medicinal product
IND investigational new drug application
INR international normalized ratio
IP Internet Protocol
IPAL investigational product accountability  log
IPM investigational product manual
IRB institutional review board
IRC internal review committee
IRT interactive response technology
ISO International Organization for Standardization
IV intravenous
K proportionality  constant for Bedside and Modified Schwartz 
Equations (kidney  function)
KDIGO Kidney  Disease: I mproving Global Outcomes
LFT liver function test
LRTD lower respiratory  track disease
LRTI lower respiratory  tract illness
LRTI -RSV RSV -associated lower respiratory  tract illness
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 104Abbreviation Term
MA-LRTI medically  attended lower respiratory  tract illness
MDR Medical Device Regulation
MedDRA Medical Dictionary  for Regulatory  Activities
mITT modified intent -to-treat
MQI medically  qualified individual
NDCMC newly  diagnosed chronic medical condition
NIMP noninvestigational medicinal product
NT neutralizing titer
PACL protocol administrative c hange letter
PBMC human peripheral blood mononuclear cell
PFS prefilled s yringe
PI principal investigator
PSSA Pfizer's Serious Adverse Event Submission Assistant
PT prothrombin time
QTL quality  tolerance limit
RCDC reverse cumulative distribution curve
RSV respiratory  syncytial virus
RSV A respiratory  syncytial virus subgroup A
RSV B respiratory  syncytial virus subgroup B
RSVpreF respiratory  syncytial virus stabilized prefusion F subunit vaccine
RTI respiratory  tract illness
RTI-RSV RSV -associated respiratory  tract illness
RT-PCR reverse transcription –polymerase chain reaction
SAE serious adverse event
SADE serious adverse device effect
SAP statistical analy sis plan
SARS -CoV -2 severe acute respiratory  syndrome coronavirus 2
Scr serum creatinine
Scys serum cy statin C
SD standard deviation
SIIV seasonal inactivated influenza vaccine
SmPC summary  of product characteristics
SoA schedule of activities
SOP standard operating procedure 
SRSD single reference safet y document
SUSAR suspected unexpected serious adverse reaction
T bili total bilirubin
Tdap tetanus toxoid, reduced diphtheria toxoid and acellular pertussis 
vaccine, adsorbed
Th1 T-helper t ype 1
Th2 T-helper t ype 2
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 105Abbreviation Term
UK United Kingdom
ULN upper limit of normal
US United States
UADE unanticipated adverse device effect
USADE unanticipated serious adverse device effect
USPI United States prescribing information
VE vaccine efficacy
WHO World Health Organization
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 10611.REFERENCES
1Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory  
infections due to respiratory  syncytial virus in y oung children: a s ystematic review and 
meta -analysis. Lancet. 2010;375(9725):1545-55.
2Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates 
of acute lower respiratory infections due to respiratory s yncytial virus in children 
younger than 5 y ears in 2019: a sy stematic anal ysis.Lancet.2022;399(10340) :2047 -64.
3Ajay i-Obe EK, Coen PG, Handa R, et al. Influenza A and respiratory  syncytial virus 
hospital burden in y oung children in East London. Epidemiol I nfect. 2008;136(8):1046 -
58.
4Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory  syncytial virus–associated 
hospitalizations among children less than 24 months of age. Pediatric s. 
2013;132(2):e341 -e48.
5Barr R, Green CA, Sande CJ, et al. Respiratory  syncy tial virus: diagnosis, prevention 
and management. Ther Adv I nfect Dis. 2019;6:2049936119865798.
6Centers for Disease Control and Prevention. People at 
high risk for RSV, RSV in infants 
and y
oung c hildren. National Center for Immunization and Respiratory  Diseases 
(NCI RD), Division of Viral Diseases. Atlanta, GA. 26 Jun 2018. Available from : 
https://www.cdc.gov/rsv/high -risk/infants- young -children.html.  Accessed: 05 Aug 
2021.
7Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory  syncytial virus 
infection in y oung children. N Engl J Med. 
2009;360(6):588 -98.
8Committee on I nfectious Diseases, Bronchiolitis Guidelines Committee. Updated 
guidance for palivizumab prophy laxis among infants and y oung children at increased 
risk of hospitalization for respiratory  syncytial virus infection. Pediatrics. 
2014;134(2):415 -20.
9Goldstein E, Finelli L , O'Halloran A, et al. Hospitalizations a ssociated with r espiratory  
syncytial virus and i nfluenza in children, including c hildren diagnosed with asthma. 
Epidemiology . 2019;30(6):918-26.
10Kristensen K, Hjuler T, Ravn H, et al. C hronic diseases, chromosomal abnormalities, 
and congenital malformations as risk factors for respiratory  syncytial virus 
hospitalization: a population -based cohort study . Clin I nfect Dis. 2012;54(6):810-7.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 10711Thwaites R, Buchan S, Fullarton J, et al. Clinical burden of severe respiratory  syncytial 
virus infection during the first 2 y ears of life in children born between 2000 and 2011 in 
Scotland. Eur J Pediatr. 2020;179(5):791 - 9.
12Manzoni P, Figueras- Aloy  J, Simões EA, et al. Defining the incidence and associated 
morbidity  and mortality  of severe respiratory  syncytial virus infection among children 
with chronic diseases. Infect Dis Ther. 2017;6(3):383 -411.
13IMpact -RSV Study  Group. Palivizumab, a humanized respiratory  syncytial virus 
monoclonal antibody ,reduces hospitalization from respiratory  syncytial virus infection 
in high
-risk infants. The IMpact -RSV Study  Group. Pediatrics. 1998;102(3 Pt 1):531 -7.
14Prescott WA Jr, Doloresco F, Brown J, et al. Cost effectiveness of respiratory  syncytial 
virus proph ylaxis: a critical and s ystematic review. Pharmacoeconomics. 
2010;28(4):279 -93.
15FDA. Beyfortus BLA BL 7611328 approval letter. 26 Sep 2022. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761328Orig1s000ltr.pd f
Accessed : 5 Feb 2024.
16Muny woki PK, Koech DC, Agoti CN, et al. The source of respiratory  syncyt ial virus 
infection in infants: a household cohort study  in rural Ken ya. J Infect Dis. 
2014;209(11):1685 -92.
17Heikkinen T, Valkonen H, Waris M, et al, eds. Transmission of respiratory sy ncytial 
virus infection within families. Open Forum Infect Dis; 2015
;2(1):ofu118.
18Hall CB, Geiman JM, Biggar R, et al. Respiratory sy ncytial virus infections within 
families. N Engl J Med. 1976;294(8):414 -9.
19FDA. Abry svo BLA BL 125769/0 approval letter. 31 May  2023. Available from: 
https://www.fda.gov/media/168890/download. Published: 31 May  2023. Accessed:
07 Aug 2023.
20FDA. Abry svo BLA BL 125769/26 assignment/prior approval supplement letter. 
21 August 2023. A vailable from: https://www.fda.gov/media/171523/download . 
Published: 21 Aug 2023. Accessed: 30 Aug 2023.
21EU.Commission implementing decision . 23August 2023. Available from: 
https://ec.europa.eu/health/documents/community -
register/2023/20230823160227/de c_160227_en.pdf .Accessed: 12 Sep 2023.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PF-06928316 (Respiratory Syncytial Virus [RSV] Vaccine )
Protocol C3671016
Final Protocol Amendment 1 , 09Feb 2024
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
Page 10822Kim HW, Canchola JG, Brandt CD, et al. Respiratory  syncytial virus disease in infants 
despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 
1969;89(4):422 -34.
23Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy  and safet y of a bivalent RSV 
prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465-77.
24Kampmann B , Madhi SA, Munjal I , et al. Bivalent prefusion F vaccine in pregnancy  to 
prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-64.
25Haerskjold A, Kristensen K, Kamper -Jørgensen M, et al. Risk Factors for hospitalization 
for respiratory  syncytial virus i nfection: a population -based cohort study of Danish 
children. Pediatr Infect Dis J. 201
6;35(1):61-5.
26US Food and Drug Administration. Guidance for industry : toxicity  grading scale for 
healthy  adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 
Rockville, MD: Center for Biologics Evaluation and Research; Sep 2007 .
27Agresti A. Introduction: distributions and inference for categorical data. Chapter 1. In: 
Agresti A, ed. Categorical data anal ysis. 2nd ed. Hoboken, NJ: John Wiley  & Sons; 
2002:1 -35.
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
Document Approval Record
Document Name:	
	


	



Document Title: !	"!#$%&!%'!$(! !#()#'(" !$)#()#' *
+(,*"!-%+*!*! !*,*"%!.&)%)*,#()//+#"'
!#))*,".! ).*"., ,#,*)%-).+ .!+ )"# +
&+#)*-)#!0. -1)#)%(.!#*"2	3,!. "'
!
Signed By: Date(GMT) Signing Capacity

$$
	7	7

 8
9
		$$
	77	
 8
9
090177e19fe66c14\Approved\Approved On: 11-Feb-2024 16:32 (GMT)
PPD
PPD